Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,29105796,area under the curve (AUC),Celecoxib showed the highest area under the curve (AUC) [146.50 ± 2.75 μg/mL*h] of all NSAID's.,Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29105796/),[μg] / [h·ml],146.50,2654,DB00482,Celecoxib
,28906164,extraction recoveries,"The mean extraction recoveries across QC levels were within 91.4%, and the matrix effects were within 94.5%.",Comparative pharmacokinetics study of anastrozole after single administration and combination with celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28906164/),%,91.4,4325,DB00482,Celecoxib
above,26281772,Recoveries,Recoveries were above 70% and no obvious matrix effects were observed.,Quantitation of celecoxib and four of its metabolites in rat blood by UPLC-MS/MS clarifies their blood distribution patterns and provides more accurate pharmacokinetics profiles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26281772/),%,70,4626,DB00482,Celecoxib
<,11334356,run cycle-time,The run cycle-time is <4 min.,Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334356/),min,4,5124,DB00482,Celecoxib
,11334356,flow-rate,"The reconstituted solution of the residue was injected onto a Shim Pack GLC-CN, C18 column and chromatographed with a mobile phase comprised of acetonitrile-1% acetic acid solution (4:1) at a flow-rate of 1 ml/min.",Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334356/),[ml] / [min],1,5125,DB00482,Celecoxib
,11334356,relative recoveries,The relative recoveries of celecoxib from human plasma ranged from 102.4 to 103.3% indicating the suitability of the method for the extraction of celecoxib and I.S. from plasma samples.,Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334356/),%,102.4 to 103.3,5126,DB00482,Celecoxib
,22251657,drug loading capacity,"The results showed that FOMC has a high drug loading capacity (0.599 g/g, drug weight/carrier weight) and the dissolution rate of CEL from FOMC was much faster than pure crystalline CEL using buffer (pH 6.8) as a dissolution medium.",Inclusion of celecoxib into fibrous ordered mesoporous carbon for enhanced oral bioavailability and reduced gastric irritancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22251657/),[g] / [g],0.599,5581,DB00482,Celecoxib
,25111199,time to progression,"A decrease in prostate-specific antigen ≥50% was observed in 82% of 39 evaluable patients, with a median time to progression of 12.3 months.",Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25111199/),month,12.3,7035,DB00482,Celecoxib
,25111199,PFS,"Median PFS and OS were 14.9 months (95% CI, 9.2-15.3 months) and 33.3 months (95% CI, 23-35.6 months), respectively.",Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25111199/),month,14,7036,DB00482,Celecoxib
,25111199,OS,"Median PFS and OS were 14.9 months (95% CI, 9.2-15.3 months) and 33.3 months (95% CI, 23-35.6 months), respectively.",Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25111199/),month,33,7037,DB00482,Celecoxib
,14768975,AUC(0-1),"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[h·ng] / [ml],4531.28,9469,DB00482,Celecoxib
,14768975,AUC(0-1),"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[h·ng] / [ml],1629.1,9470,DB00482,Celecoxib
,14768975,AUC(0-infinity),"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[h·ng] / [ml],4632.42,9471,DB00482,Celecoxib
,14768975,AUC(0-infinity),"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[h·ng] / [ml],1629.46,9472,DB00482,Celecoxib
,14768975,Cmax,"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[ng] / [ml],544.89,9473,DB00482,Celecoxib
,14768975,Cmax,"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[ng] / [ml],238.61,9474,DB00482,Celecoxib
,14768975,t(1/2),"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),h,9.3,9475,DB00482,Celecoxib
,14768975,t(1/2),"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),h,4.0,9476,DB00482,Celecoxib
,14768975,Cl/f,"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[l] / [h],43.14,9477,DB00482,Celecoxib
,14768975,Cl/f,"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[l] / [h],122.85,9478,DB00482,Celecoxib
,14768975,"time to reach peak concentration, tmax","However, time to reach peak concentration, tmax (4 +/- 0.88 vs 4 +/- 0.83 h) and volume of distribution Vd/f (583 +/- 251 vs 710 +/- 690 l/kg) were not affected significantly.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),h,4,9479,DB00482,Celecoxib
,14768975,"time to reach peak concentration, tmax","However, time to reach peak concentration, tmax (4 +/- 0.88 vs 4 +/- 0.83 h) and volume of distribution Vd/f (583 +/- 251 vs 710 +/- 690 l/kg) were not affected significantly.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),h,4,9480,DB00482,Celecoxib
,14768975,volume of distribution Vd/f,"However, time to reach peak concentration, tmax (4 +/- 0.88 vs 4 +/- 0.83 h) and volume of distribution Vd/f (583 +/- 251 vs 710 +/- 690 l/kg) were not affected significantly.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[l] / [kg],583,9481,DB00482,Celecoxib
,14768975,volume of distribution Vd/f,"However, time to reach peak concentration, tmax (4 +/- 0.88 vs 4 +/- 0.83 h) and volume of distribution Vd/f (583 +/- 251 vs 710 +/- 690 l/kg) were not affected significantly.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[l] / [kg],710,9482,DB00482,Celecoxib
,16173491,maximum concentrations (Cmax,"Administration of multiple doses of celecoxib resulted in a significant decrease (40%) in median area under the curve (AUC) values and a corresponding decrease in median maximum concentrations (Cmax; 2,620 to 2,032 ng/mL) between the 1st and 10th doses.",Plasma pharmacokinetics and synovial fluid concentrations after oral administration of single and multiple doses of celecoxib in greyhounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16173491/),[ng] / [ml],"2,620 to 2,032",12325,DB00482,Celecoxib
,32264977,flow rate,The procedure was performed in less than 3 min with a gradient elution pumped at a flow rate of 0.4 ml/min.,Determination of parecoxib and valdecoxib in rat plasma by UPLC-MS/MS and its application to pharmacokinetics studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32264977/),[ml] / [min],0.4,12508,DB00482,Celecoxib
,12504784,vascular leakage,"Furthermore, the retinal vascular leakage estimated as vitreous to plasma protein ratio increased in diabetic animals from 0.35+/-0.1 to 1.1+/-0.1 and celecoxib treatment significantly decreased this ratio to 0.4+/-0.1.","Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504784/),,0.35,13956,DB00482,Celecoxib
,12504784,vascular leakage,"Furthermore, the retinal vascular leakage estimated as vitreous to plasma protein ratio increased in diabetic animals from 0.35+/-0.1 to 1.1+/-0.1 and celecoxib treatment significantly decreased this ratio to 0.4+/-0.1.","Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504784/),,1.1,13957,DB00482,Celecoxib
,12504784,vascular leakage,"Furthermore, the retinal vascular leakage estimated as vitreous to plasma protein ratio increased in diabetic animals from 0.35+/-0.1 to 1.1+/-0.1 and celecoxib treatment significantly decreased this ratio to 0.4+/-0.1.","Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504784/),,0.4,13958,DB00482,Celecoxib
,12504784,ratio,"Furthermore, the retinal vascular leakage estimated as vitreous to plasma protein ratio increased in diabetic animals from 0.35+/-0.1 to 1.1+/-0.1 and celecoxib treatment significantly decreased this ratio to 0.4+/-0.1.","Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504784/),,0.4,13959,DB00482,Celecoxib
,12504784,levels,"Celecoxib levels were 24.8+/-6.6, 1.9+/-1, 1.7+/-0.8, and 6.9+/-0.9 ng/mg in the retina, vitreous, lens, and cornea, respectively.","Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504784/),,1,13960,DB00482,Celecoxib
,12504784,levels,"Celecoxib levels were 24.8+/-6.6, 1.9+/-1, 1.7+/-0.8, and 6.9+/-0.9 ng/mg in the retina, vitreous, lens, and cornea, respectively.","Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504784/),,1.7,13961,DB00482,Celecoxib
,12504784,levels,"Celecoxib levels were 24.8+/-6.6, 1.9+/-1, 1.7+/-0.8, and 6.9+/-0.9 ng/mg in the retina, vitreous, lens, and cornea, respectively.","Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504784/),,6.9,13962,DB00482,Celecoxib
,12587957,peak plasma concentration (Cmax,The immediate release capsules of celecoxib might have disintegrated very fast in GI tract and absorbed quickly from stomach and small intestine thereby producing peak plasma concentration (Cmax of 478 +/- 57 ng/ml) within 3.8 +/- 0.1 h (Tmax).,In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587957/),[ng] / [ml],478,16460,DB00482,Celecoxib
,12587957,Tmax,The immediate release capsules of celecoxib might have disintegrated very fast in GI tract and absorbed quickly from stomach and small intestine thereby producing peak plasma concentration (Cmax of 478 +/- 57 ng/ml) within 3.8 +/- 0.1 h (Tmax).,In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587957/),h,3.8,16461,DB00482,Celecoxib
,12587957,peak concentration (Cmax),"Though celecoxib could be seen in plasma after oral administration of colon-targeted tablet-20 or colon-targeted tablet-30 between 1 and 2 h, low levels of drug were observed upto 8 h resulting in peak concentration (Cmax) of 78 +/- 6 ng/ml or 88 +/- 15 ng/ml at 10.5 +/- 1.9 h or 13.5 +/- 1.4 h (Tmax) respectively, whereas the immediate release capsules produced peak plasma concentration (Cmax) of 478 +/- 57 ng/ml at 3.8 +/- 0.1 h (Tmax).",In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587957/),[ng] / [ml],78,16462,DB00482,Celecoxib
,12587957,peak concentration (Cmax),"Though celecoxib could be seen in plasma after oral administration of colon-targeted tablet-20 or colon-targeted tablet-30 between 1 and 2 h, low levels of drug were observed upto 8 h resulting in peak concentration (Cmax) of 78 +/- 6 ng/ml or 88 +/- 15 ng/ml at 10.5 +/- 1.9 h or 13.5 +/- 1.4 h (Tmax) respectively, whereas the immediate release capsules produced peak plasma concentration (Cmax) of 478 +/- 57 ng/ml at 3.8 +/- 0.1 h (Tmax).",In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587957/),[ng] / [ml],88,16463,DB00482,Celecoxib
,12587957,Tmax,"Though celecoxib could be seen in plasma after oral administration of colon-targeted tablet-20 or colon-targeted tablet-30 between 1 and 2 h, low levels of drug were observed upto 8 h resulting in peak concentration (Cmax) of 78 +/- 6 ng/ml or 88 +/- 15 ng/ml at 10.5 +/- 1.9 h or 13.5 +/- 1.4 h (Tmax) respectively, whereas the immediate release capsules produced peak plasma concentration (Cmax) of 478 +/- 57 ng/ml at 3.8 +/- 0.1 h (Tmax).",In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587957/),h,13.5,16464,DB00482,Celecoxib
,12587957,peak plasma concentration (Cmax),"Though celecoxib could be seen in plasma after oral administration of colon-targeted tablet-20 or colon-targeted tablet-30 between 1 and 2 h, low levels of drug were observed upto 8 h resulting in peak concentration (Cmax) of 78 +/- 6 ng/ml or 88 +/- 15 ng/ml at 10.5 +/- 1.9 h or 13.5 +/- 1.4 h (Tmax) respectively, whereas the immediate release capsules produced peak plasma concentration (Cmax) of 478 +/- 57 ng/ml at 3.8 +/- 0.1 h (Tmax).",In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587957/),[ng] / [ml],478,16465,DB00482,Celecoxib
,12587957,Tmax,"Though celecoxib could be seen in plasma after oral administration of colon-targeted tablet-20 or colon-targeted tablet-30 between 1 and 2 h, low levels of drug were observed upto 8 h resulting in peak concentration (Cmax) of 78 +/- 6 ng/ml or 88 +/- 15 ng/ml at 10.5 +/- 1.9 h or 13.5 +/- 1.4 h (Tmax) respectively, whereas the immediate release capsules produced peak plasma concentration (Cmax) of 478 +/- 57 ng/ml at 3.8 +/- 0.1 h (Tmax).",In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587957/),h,3.8,16466,DB00482,Celecoxib
,32131561,stability,The results show that Egg yolk phosphatidylcholine PC98T (PC) significantly increased the stability of CX-PC-casein nanoparticles (NPs) (192.6 nm) from 5 min (CX-β-casein-NPs) to 2.5 h at 37 °C.,Structural Modification of Nanomicelles through Phosphatidylcholine: The Enhanced Drug-Loading Capacity and Anticancer Activity of Celecoxib-Casein Nanoparticles for the Intravenous Delivery of Celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32131561/),min,5,19344,DB00482,Celecoxib
,32131561,stability,The results show that Egg yolk phosphatidylcholine PC98T (PC) significantly increased the stability of CX-PC-casein nanoparticles (NPs) (192.6 nm) from 5 min (CX-β-casein-NPs) to 2.5 h at 37 °C.,Structural Modification of Nanomicelles through Phosphatidylcholine: The Enhanced Drug-Loading Capacity and Anticancer Activity of Celecoxib-Casein Nanoparticles for the Intravenous Delivery of Celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32131561/),h,2.5,19345,DB00482,Celecoxib
,32131561,tumor inhibition rate,"When CX-PC-casein-NPs were intravenously administrated to mice implanted with A375 tumors (CX dose = 16 mg/kg bodyweight), the tumor inhibition rate reached 56.2%, which was comparable to that of paclitaxel (57.3%) at a dose of 4 mg/kg bodyweight.",Structural Modification of Nanomicelles through Phosphatidylcholine: The Enhanced Drug-Loading Capacity and Anticancer Activity of Celecoxib-Casein Nanoparticles for the Intravenous Delivery of Celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32131561/),%,56.2,19346,DB00482,Celecoxib
,32131561,tumor inhibition rate,"When CX-PC-casein-NPs were intravenously administrated to mice implanted with A375 tumors (CX dose = 16 mg/kg bodyweight), the tumor inhibition rate reached 56.2%, which was comparable to that of paclitaxel (57.3%) at a dose of 4 mg/kg bodyweight.",Structural Modification of Nanomicelles through Phosphatidylcholine: The Enhanced Drug-Loading Capacity and Anticancer Activity of Celecoxib-Casein Nanoparticles for the Intravenous Delivery of Celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32131561/),%,57.3,19347,DB00482,Celecoxib
,12369449,flow rate,The mobile phase comprised of 10 mM potassium dihydrogen ortho phosphate (pH 3.2) and acetonitrile (50:50 v/v) with a flow rate of 1 ml/min.,Validated HPLC method for the determination of celecoxib in human serum and its application in a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369449/),[ml] / [min],1,19839,DB00482,Celecoxib
,12369449,Retention times,"Retention times of celecoxib and tolbutamide were 9.6 and 3.5 min, respectively.",Validated HPLC method for the determination of celecoxib in human serum and its application in a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369449/),min,9.6,19840,DB00482,Celecoxib
,12369449,Retention times,"Retention times of celecoxib and tolbutamide were 9.6 and 3.5 min, respectively.",Validated HPLC method for the determination of celecoxib in human serum and its application in a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369449/),min,3.5,19841,DB00482,Celecoxib
,26355768,flow rate,"Chromatographic separation was achieved on Acquity BEH™ C18 (50×2.1 mm, 1.7 μm) column using gradient mobile phase of acetonitrile and water (containing 0.1% formic acid) at flow rate of 0.3 mL/min.","Preclinical pharmacokinetics, tissue distribution and excretion studies of a novel anti-candidal agent-thiosemicarbazide derivative of isoniazid (TSC-INH) by validated UPLC-MS/MS assay. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26355768/),[ml] / [min],0.3,19859,DB00482,Celecoxib
,26355768,m/z,The MRM transitions were monitored at m/z 305.00→135.89 for TSC-INH and m/z 380.08→316.03 for IS in ESI negative mode.,"Preclinical pharmacokinetics, tissue distribution and excretion studies of a novel anti-candidal agent-thiosemicarbazide derivative of isoniazid (TSC-INH) by validated UPLC-MS/MS assay. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26355768/),,305.00,19860,DB00482,Celecoxib
,26355768,m/z,The MRM transitions were monitored at m/z 305.00→135.89 for TSC-INH and m/z 380.08→316.03 for IS in ESI negative mode.,"Preclinical pharmacokinetics, tissue distribution and excretion studies of a novel anti-candidal agent-thiosemicarbazide derivative of isoniazid (TSC-INH) by validated UPLC-MS/MS assay. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26355768/),,135.89,19861,DB00482,Celecoxib
,26355768,m/z,The MRM transitions were monitored at m/z 305.00→135.89 for TSC-INH and m/z 380.08→316.03 for IS in ESI negative mode.,"Preclinical pharmacokinetics, tissue distribution and excretion studies of a novel anti-candidal agent-thiosemicarbazide derivative of isoniazid (TSC-INH) by validated UPLC-MS/MS assay. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26355768/),,380.08,19862,DB00482,Celecoxib
,26355768,m/z,The MRM transitions were monitored at m/z 305.00→135.89 for TSC-INH and m/z 380.08→316.03 for IS in ESI negative mode.,"Preclinical pharmacokinetics, tissue distribution and excretion studies of a novel anti-candidal agent-thiosemicarbazide derivative of isoniazid (TSC-INH) by validated UPLC-MS/MS assay. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26355768/),,316.03,19863,DB00482,Celecoxib
,26355768,absolute bioavailability,The pharmacokinetic study showed that the compound TSC-INH was orally active with 66% absolute bioavailability in rats.,"Preclinical pharmacokinetics, tissue distribution and excretion studies of a novel anti-candidal agent-thiosemicarbazide derivative of isoniazid (TSC-INH) by validated UPLC-MS/MS assay. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26355768/),%,66,19864,DB00482,Celecoxib
,26355768,peak plasma concentration,It was rapidly absorbed with peak plasma concentration of 1985.92 ng/mL achieved within 1 h after single oral dose (10 mg/kg) administration.,"Preclinical pharmacokinetics, tissue distribution and excretion studies of a novel anti-candidal agent-thiosemicarbazide derivative of isoniazid (TSC-INH) by validated UPLC-MS/MS assay. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26355768/),[ng] / [ml],1985.92,19865,DB00482,Celecoxib
,31912248,flow rate,"Celecoxib (CEB) was selected as a model drug, and in vitro dissolution was performed using the novel dissolution apparatus with acetate buffers at pH 4.5 containing Tween 80 (0.15%, w/v), at a flow rate of 30 mL/min and an agitation rate of 50 rpm.",Development of a Two-Compartment System In vitro Dissolution Test and Correlation with In vivo Pharmacokinetic Studies for Celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912248/),[ml] / [min],30,21450,DB00482,Celecoxib
,24342124,AUC,"AUC (139.70±24.97 μg h/mL), Cmax (42.99±2.98 μg/mL), and CLoral (0.08±0.02 L/h/kg) values of diclofenac in diclofenac plus rebamipide group altered when compared to those of diclofenac treated groups.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[h·μg] / [ml],139.70,22350,DB00482,Celecoxib
,24342124,Cmax,"AUC (139.70±24.97 μg h/mL), Cmax (42.99±2.98 μg/mL), and CLoral (0.08±0.02 L/h/kg) values of diclofenac in diclofenac plus rebamipide group altered when compared to those of diclofenac treated groups.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[μg] / [ml],42.99,22351,DB00482,Celecoxib
,24342124,CLoral,"AUC (139.70±24.97 μg h/mL), Cmax (42.99±2.98 μg/mL), and CLoral (0.08±0.02 L/h/kg) values of diclofenac in diclofenac plus rebamipide group altered when compared to those of diclofenac treated groups.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[l] / [h·kg],0.08,22352,DB00482,Celecoxib
,24342124,Cmax,"Cmax (7.80±1.22 μg/mL), AUC (56.46±7.30 μg h/mL), Vd/F (7.55±1.37 L/kg), and CLoral (0.58±0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[μg] / [ml],7.80,22353,DB00482,Celecoxib
,24342124,AUC,"Cmax (7.80±1.22 μg/mL), AUC (56.46±7.30 μg h/mL), Vd/F (7.55±1.37 L/kg), and CLoral (0.58±0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[h·μg] / [ml],56.46,22354,DB00482,Celecoxib
,24342124,Vd/F,"Cmax (7.80±1.22 μg/mL), AUC (56.46±7.30 μg h/mL), Vd/F (7.55±1.37 L/kg), and CLoral (0.58±0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[l] / [kg],7.55,22355,DB00482,Celecoxib
,24342124,CLoral,"Cmax (7.80±1.22 μg/mL), AUC (56.46±7.30 μg h/mL), Vd/F (7.55±1.37 L/kg), and CLoral (0.58±0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[l] / [h·kg],0.58,22356,DB00482,Celecoxib
,16838266,flow gradient,"The chromatographic run time was less than 20 min using flow gradient (0.0-1.60 mL/min) with a mobile phase consisting of 0.01 M ammonium acetate:acetonitrile:methanol (50:40:10, v/v/v) and UV detection at 275 nm.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),[ml] / [min],0.0-1.60,22411,DB00482,Celecoxib
,16838266,Nominal retention times,"Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),min,6.7,22412,DB00482,Celecoxib
,16838266,Nominal retention times,"Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),min,13.9,22413,DB00482,Celecoxib
,16838266,Nominal retention times,"Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),min,16.4,22414,DB00482,Celecoxib
greater,16838266,Absolute recovery,Absolute recovery of both analytes and IS was greater than 90%.,Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),%,90,22415,DB00482,Celecoxib
,31226426,SBET,"The SBET and Vt of CSMSNs were 890.65 m2/g and 1.23 cm3/g, respectively.",In Vitro and In Vivo Evaluation of Core-Shell Mesoporous Silica as a Promising Water-Insoluble Drug Delivery System: Improving the Dissolution Rate and Bioavailability of Celecoxib With Needle-Like Crystallinity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31226426/),[m2] / [g],890.65,22781,DB00482,Celecoxib
,31226426,Vt,"The SBET and Vt of CSMSNs were 890.65 m2/g and 1.23 cm3/g, respectively.",In Vitro and In Vivo Evaluation of Core-Shell Mesoporous Silica as a Promising Water-Insoluble Drug Delivery System: Improving the Dissolution Rate and Bioavailability of Celecoxib With Needle-Like Crystallinity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31226426/),[cm3] / [g],1.23,22782,DB00482,Celecoxib
,30877972,IC50,"Among them, compound A33 displayed the most potency against cancer cell lines (IC50 = 6.43-10.97 μM for F10, HeLa, A549 and MCF-7 cells), lower toxicity to non-cancer cells than celecoxib (A33: IC50 = 194.01 μM vs.celecoxib: IC50 = 97.87 μM for 293T cells), and excellent inhibitory activities on COX-2 (IC50 = 0.17 μM) and 5-LOX (IC50 = 0.68 μM).","Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30877972/),μM,6.43-10.97,28132,DB00482,Celecoxib
,30877972,IC50,"Among them, compound A33 displayed the most potency against cancer cell lines (IC50 = 6.43-10.97 μM for F10, HeLa, A549 and MCF-7 cells), lower toxicity to non-cancer cells than celecoxib (A33: IC50 = 194.01 μM vs.celecoxib: IC50 = 97.87 μM for 293T cells), and excellent inhibitory activities on COX-2 (IC50 = 0.17 μM) and 5-LOX (IC50 = 0.68 μM).","Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30877972/),μM,194.01,28133,DB00482,Celecoxib
,30877972,IC50,"Among them, compound A33 displayed the most potency against cancer cell lines (IC50 = 6.43-10.97 μM for F10, HeLa, A549 and MCF-7 cells), lower toxicity to non-cancer cells than celecoxib (A33: IC50 = 194.01 μM vs.celecoxib: IC50 = 97.87 μM for 293T cells), and excellent inhibitory activities on COX-2 (IC50 = 0.17 μM) and 5-LOX (IC50 = 0.68 μM).","Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30877972/),μM,97.87,28134,DB00482,Celecoxib
,30877972,IC50,"Among them, compound A33 displayed the most potency against cancer cell lines (IC50 = 6.43-10.97 μM for F10, HeLa, A549 and MCF-7 cells), lower toxicity to non-cancer cells than celecoxib (A33: IC50 = 194.01 μM vs.celecoxib: IC50 = 97.87 μM for 293T cells), and excellent inhibitory activities on COX-2 (IC50 = 0.17 μM) and 5-LOX (IC50 = 0.68 μM).","Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30877972/),μM,0.17,28135,DB00482,Celecoxib
,30877972,IC50,"Among them, compound A33 displayed the most potency against cancer cell lines (IC50 = 6.43-10.97 μM for F10, HeLa, A549 and MCF-7 cells), lower toxicity to non-cancer cells than celecoxib (A33: IC50 = 194.01 μM vs.celecoxib: IC50 = 97.87 μM for 293T cells), and excellent inhibitory activities on COX-2 (IC50 = 0.17 μM) and 5-LOX (IC50 = 0.68 μM).","Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30877972/),μM,0.68,28136,DB00482,Celecoxib
,20058106,entrapment percent,The average entrapment percent of celecoxib proniosome-derived niosomes was about 95%.,In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20058106/),%,95,39188,DB00482,Celecoxib
,20058106,relative bioavailability,The mean relative bioavailability of the proniosomal formulation to the conventional capsule was 172.06 +/- 0.14%.,In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20058106/),%,172.06,39189,DB00482,Celecoxib
,11303053,absolute bioavailability,The absolute bioavailability of celecoxib was higher when given as a solution (64--88%) compared with capsule (22--40%).,Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11303053/),%,64-,41890,DB00482,Celecoxib
,11303053,absolute bioavailability,The absolute bioavailability of celecoxib was higher when given as a solution (64--88%) compared with capsule (22--40%).,Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11303053/),%,88,41891,DB00482,Celecoxib
,11303053,absolute bioavailability,The absolute bioavailability of celecoxib was higher when given as a solution (64--88%) compared with capsule (22--40%).,Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11303053/),,22,41892,DB00482,Celecoxib
,12523466,elimination half-life,We analyzed samples of her breast milk and found a concentration of 133 ng/ml at approximately 5 hours after a 100-mg dose and an elimination half-life of 4.0-6.5 hours.,Celecoxib in human milk: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523466/),h,4.0-6.5,44756,DB00482,Celecoxib
,11302784,oral bioavailability,"In control rats, CEL had an oral bioavailability of 0.59 due mainly to presystemic hepatic metabolism.",Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302784/),,0.59,44767,DB00482,Celecoxib
,11302784,terminal t(1/2),"A multi-compartmental disposition kinetics with an average terminal t(1/2) of 2.8 +/- 0.7 h, and volume of distribution of 2.3 +/- 0.6 L/kg were found.",Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302784/),h,2.8,44768,DB00482,Celecoxib
,11302784,volume of distribution,"A multi-compartmental disposition kinetics with an average terminal t(1/2) of 2.8 +/- 0.7 h, and volume of distribution of 2.3 +/- 0.6 L/kg were found.",Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302784/),[l] / [kg],2.3,44769,DB00482,Celecoxib
,16580269,analytical recovery,"The method involves simple, one-step extraction procedure, and analytical recovery was 100.5 +/- 1.3%.",Simple and rapid high-performance liquid chromatographic method for determination of celecoxib in plasma using UV detection: application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580269/),%,100.5,48983,DB00482,Celecoxib
,15553225,AUC(0-infinity) ratios,"For the subconjunctivally dosed (ipsilateral) eye, the AUC(0-infinity) ratios between subconjunctival and intraperitoneal groups were 0.8 +/- 0.1, 53 +/- 4, 54 +/- 8, 145 +/- 21, 61 +/- 16, and 52 +/- 6 for plasma, sclera, retina, vitreous, lens, and cornea, respectively.",Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553225/),,0.8,54104,DB00482,Celecoxib
,15553225,AUC(0-infinity) ratios,"For the subconjunctivally dosed (ipsilateral) eye, the AUC(0-infinity) ratios between subconjunctival and intraperitoneal groups were 0.8 +/- 0.1, 53 +/- 4, 54 +/- 8, 145 +/- 21, 61 +/- 16, and 52 +/- 6 for plasma, sclera, retina, vitreous, lens, and cornea, respectively.",Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553225/),,53,54105,DB00482,Celecoxib
,15553225,AUC(0-infinity) ratios,"For the subconjunctivally dosed (ipsilateral) eye, the AUC(0-infinity) ratios between subconjunctival and intraperitoneal groups were 0.8 +/- 0.1, 53 +/- 4, 54 +/- 8, 145 +/- 21, 61 +/- 16, and 52 +/- 6 for plasma, sclera, retina, vitreous, lens, and cornea, respectively.",Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553225/),,54,54106,DB00482,Celecoxib
,15553225,AUC(0-infinity) ratios,"For the subconjunctivally dosed (ipsilateral) eye, the AUC(0-infinity) ratios between subconjunctival and intraperitoneal groups were 0.8 +/- 0.1, 53 +/- 4, 54 +/- 8, 145 +/- 21, 61 +/- 16, and 52 +/- 6 for plasma, sclera, retina, vitreous, lens, and cornea, respectively.",Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553225/),,145,54107,DB00482,Celecoxib
,15553225,AUC(0-infinity) ratios,"For the subconjunctivally dosed (ipsilateral) eye, the AUC(0-infinity) ratios between subconjunctival and intraperitoneal groups were 0.8 +/- 0.1, 53 +/- 4, 54 +/- 8, 145 +/- 21, 61 +/- 16, and 52 +/- 6 for plasma, sclera, retina, vitreous, lens, and cornea, respectively.",Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553225/),,61,54108,DB00482,Celecoxib
,15553225,AUC(0-infinity) ratios,"For the subconjunctivally dosed (ipsilateral) eye, the AUC(0-infinity) ratios between subconjunctival and intraperitoneal groups were 0.8 +/- 0.1, 53 +/- 4, 54 +/- 8, 145 +/- 21, 61 +/- 16, and 52 +/- 6 for plasma, sclera, retina, vitreous, lens, and cornea, respectively.",Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553225/),,52,54109,DB00482,Celecoxib
,15553225,AUC0-infinity ratios,"For the contralateral ocular tissues, the AUC0-infinity ratios were 1.2 +/- 03, 11 +/- 0.3, 1.1 +/- 0.4, 1.0 +/- 0.3, and 1.2 +/- 0.3 in the sclera, retina, vitreous, lens, and the cornea, respectively, between the subconjunctival and the intraperitoneal groups.",Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553225/),,1.2,54110,DB00482,Celecoxib
,15553225,AUC0-infinity ratios,"For the contralateral ocular tissues, the AUC0-infinity ratios were 1.2 +/- 03, 11 +/- 0.3, 1.1 +/- 0.4, 1.0 +/- 0.3, and 1.2 +/- 0.3 in the sclera, retina, vitreous, lens, and the cornea, respectively, between the subconjunctival and the intraperitoneal groups.",Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553225/),,11,54111,DB00482,Celecoxib
,15553225,AUC0-infinity ratios,"For the contralateral ocular tissues, the AUC0-infinity ratios were 1.2 +/- 03, 11 +/- 0.3, 1.1 +/- 0.4, 1.0 +/- 0.3, and 1.2 +/- 0.3 in the sclera, retina, vitreous, lens, and the cornea, respectively, between the subconjunctival and the intraperitoneal groups.",Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553225/),,1.1,54112,DB00482,Celecoxib
,15553225,AUC0-infinity ratios,"For the contralateral ocular tissues, the AUC0-infinity ratios were 1.2 +/- 03, 11 +/- 0.3, 1.1 +/- 0.4, 1.0 +/- 0.3, and 1.2 +/- 0.3 in the sclera, retina, vitreous, lens, and the cornea, respectively, between the subconjunctival and the intraperitoneal groups.",Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553225/),,1.0,54113,DB00482,Celecoxib
,15553225,AUC0-infinity ratios,"For the contralateral ocular tissues, the AUC0-infinity ratios were 1.2 +/- 03, 11 +/- 0.3, 1.1 +/- 0.4, 1.0 +/- 0.3, and 1.2 +/- 0.3 in the sclera, retina, vitreous, lens, and the cornea, respectively, between the subconjunctival and the intraperitoneal groups.",Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553225/),,1.2,54114,DB00482,Celecoxib
,34163139,flow rate,"The column was Acquity UPLC BEH C18 column and the mobile phase was acetonitrile-formic acid with gradient mode, and the flow rate was set at 0.4 mL/min.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),[ml] / [min],0.4,59672,DB00482,Celecoxib
,34163139,m/,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,381.10,59673,DB00482,Celecoxib
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,246.20,59674,DB00482,Celecoxib
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,147.00,59675,DB00482,Celecoxib
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,201.10,59676,DB00482,Celecoxib
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,94.90,59677,DB00482,Celecoxib
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,326.10,59678,DB00482,Celecoxib
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,291.10,59679,DB00482,Celecoxib
more,34163139,extraction recovery,"The extraction recovery was more than 79%, and the matrix effect was around 100%.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),%,79,59680,DB00482,Celecoxib
,32762829,flow rate,"The HPLC assay was performed isocratically on a reversed-phase C18 μ-Bondapack column using a mobile phase of acetonitrile:water (45:55, v/v) at a flow rate of 1.2 mL/min, and the analytes were detected at 230 nm.",Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32762829/),[ml] / [min],1.2,71765,DB00482,Celecoxib
,32762829,retention times,"The retention times for docetaxel, paclitaxel, and celecoxib were 10.94, 12.4, and 16.81 min, respectively.",Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32762829/),min,10.94,71766,DB00482,Celecoxib
,32762829,retention times,"The retention times for docetaxel, paclitaxel, and celecoxib were 10.94, 12.4, and 16.81 min, respectively.",Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32762829/),min,12.4,71767,DB00482,Celecoxib
,32762829,retention times,"The retention times for docetaxel, paclitaxel, and celecoxib were 10.94, 12.4, and 16.81 min, respectively.",Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32762829/),min,16.81,71768,DB00482,Celecoxib
,21863477,time to maximum drug concentration (Tmax),"Nanoparticles dosed orally in aqueous suspensions provided higher systemic exposure and faster attainment of peak plasma concentrations than commercial capsules, with median time to maximum drug concentration (Tmax) of 0.75 h in humans for nanoparticles vs. 3 h for commercial capsules.","Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21863477/),h,0.75,72173,DB00482,Celecoxib
,21863477,time to maximum drug concentration (Tmax),"Nanoparticles dosed orally in aqueous suspensions provided higher systemic exposure and faster attainment of peak plasma concentrations than commercial capsules, with median time to maximum drug concentration (Tmax) of 0.75 h in humans for nanoparticles vs. 3 h for commercial capsules.","Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21863477/),h,3,72174,DB00482,Celecoxib
,10772629,Total mean percent recovery,Total mean percent recovery of the radioactive dose was about 100% for both the male rat (9.6% in urine; 91.7% in feces) and the female rat (10.6% in urine; 91.3% in feces).,"Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772629/),%,100,73932,DB00482,Celecoxib
,10772629,Total mean percent recovery,Total mean percent recovery of the radioactive dose was about 100% for both the male rat (9.6% in urine; 91.7% in feces) and the female rat (10.6% in urine; 91.3% in feces).,"Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772629/),%,9.6,73933,DB00482,Celecoxib
,10772629,Total mean percent recovery,Total mean percent recovery of the radioactive dose was about 100% for both the male rat (9.6% in urine; 91.7% in feces) and the female rat (10.6% in urine; 91.3% in feces).,"Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772629/),%,91.7,73934,DB00482,Celecoxib
,10772629,Total mean percent recovery,Total mean percent recovery of the radioactive dose was about 100% for both the male rat (9.6% in urine; 91.7% in feces) and the female rat (10.6% in urine; 91.3% in feces).,"Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772629/),%,10.6,73935,DB00482,Celecoxib
,10772629,Total mean percent recovery,Total mean percent recovery of the radioactive dose was about 100% for both the male rat (9.6% in urine; 91.7% in feces) and the female rat (10.6% in urine; 91.3% in feces).,"Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772629/),%,91.3,73936,DB00482,Celecoxib
,17435173,IC50,"In vitro, metabolites elicited no substantial COX-1/COX-2 selectivity with MAA (IC50=2.55 micromol/L for COX-1; IC50=4.65 micromol/L for COX-2), being approximately 8.2- or 9-fold more potent than AA.",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),[μM] / [l],2.55,76643,DB00482,Celecoxib
,17435173,IC50,"In vitro, metabolites elicited no substantial COX-1/COX-2 selectivity with MAA (IC50=2.55 micromol/L for COX-1; IC50=4.65 micromol/L for COX-2), being approximately 8.2- or 9-fold more potent than AA.",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),[μM] / [l],4.65,76644,DB00482,Celecoxib
,17435173,IC50,COX inhibition correlated with MAA plasma levels (ex vivo IC50 values of 1.03 micromol/L [COX-1] and 0.87 micromol/L [COX-2]).,Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),[μM] / [l],1.03,76645,DB00482,Celecoxib
,17435173,IC50,COX inhibition correlated with MAA plasma levels (ex vivo IC50 values of 1.03 micromol/L [COX-1] and 0.87 micromol/L [COX-2]).,Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),[μM] / [l],0.87,76646,DB00482,Celecoxib
,17435173,Maximal inhibitions,"Maximal inhibitions of COX-1 and COX-2 were 94% and 87% (500 mg), 97% and 94% (1000 mg).",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),%,94,76647,DB00482,Celecoxib
,17435173,Maximal inhibitions,"Maximal inhibitions of COX-1 and COX-2 were 94% and 87% (500 mg), 97% and 94% (1000 mg).",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),%,87,76648,DB00482,Celecoxib
,17435173,Maximal inhibitions,"Maximal inhibitions of COX-1 and COX-2 were 94% and 87% (500 mg), 97% and 94% (1000 mg).",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),%,97,76649,DB00482,Celecoxib
,17161982,flow rate,"The chromatographic separation was performed on a Kromasil C18 column (250.0 mm x 4.6 mm, 5.0 microm) with a mobile phase gradient consisting of water and methanol at a flow rate of 1 ml min(-1).","Determination of lefucoxib in rat plasma, urine, and feces by high-performance liquid chromatography with fluorescence detection: application in pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17161982/),[ml] / [min],1,77131,DB00482,Celecoxib
,17161982,limit of quant,The limit of quantification was 5.0 ng ml(-1).,"Determination of lefucoxib in rat plasma, urine, and feces by high-performance liquid chromatography with fluorescence detection: application in pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17161982/),[ng] / [ml],5.0,77132,DB00482,Celecoxib
,17161982,Relative recoveries,"Relative recoveries ranged from 97.9% to 108.1%, and absolute recoveries were about 70.0% both with and without internal standard.","Determination of lefucoxib in rat plasma, urine, and feces by high-performance liquid chromatography with fluorescence detection: application in pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17161982/),%,97.9,77133,DB00482,Celecoxib
,17161982,Relative recoveries,"Relative recoveries ranged from 97.9% to 108.1%, and absolute recoveries were about 70.0% both with and without internal standard.","Determination of lefucoxib in rat plasma, urine, and feces by high-performance liquid chromatography with fluorescence detection: application in pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17161982/),%,108.1,77134,DB00482,Celecoxib
,17161982,absolute recoveries,"Relative recoveries ranged from 97.9% to 108.1%, and absolute recoveries were about 70.0% both with and without internal standard.","Determination of lefucoxib in rat plasma, urine, and feces by high-performance liquid chromatography with fluorescence detection: application in pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17161982/),%,70.0,77135,DB00482,Celecoxib
,23353808,Cmax,"Comparable bioavailability was observed between the SLH microparticle formulation and a conventional Capmul lipid solution, however, plasma concentrations were observed to be higher (Cmax, 1.1±0.06 vs. 0.8±0.03μg/mL) (p≤0.05) with the SLH microparticle system.",Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23353808/),[μg] / [ml],1.1,79196,DB00482,Celecoxib
,23353808,Cmax,"Comparable bioavailability was observed between the SLH microparticle formulation and a conventional Capmul lipid solution, however, plasma concentrations were observed to be higher (Cmax, 1.1±0.06 vs. 0.8±0.03μg/mL) (p≤0.05) with the SLH microparticle system.",Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23353808/),[μg] / [ml],0.8,79197,DB00482,Celecoxib
,18969115,recovery,Repeatability was examined for 1 x 10(-8) M CXB drug solution after 30 s pre-concentration and a mean recovery of 99.4+/-0.4% (n=5) was achieved.,Adsorptive stripping voltammetric determination of the anti-inflammatory drug celecoxib in pharmaceutical formulation and human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969115/),%,99.4,79594,DB00482,Celecoxib
,18969115,detection limit,"For 90 s preconcentration, a linear concentration range of 1 x 10(-9)-2 x 10(-8) M CXB and a detection limit of 1.86 x 10(-10) M were achieved.",Adsorptive stripping voltammetric determination of the anti-inflammatory drug celecoxib in pharmaceutical formulation and human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969115/),M,1.86 x 10(-10),79595,DB00482,Celecoxib
,18969115,recoveries,"The proposed procedure was successfully applied for the determination of the drug in capsules and human serum with mean recoveries of 101.5+/-0.6 and 98.8+/-1.1%, respectively.",Adsorptive stripping voltammetric determination of the anti-inflammatory drug celecoxib in pharmaceutical formulation and human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969115/),%,101.5,79596,DB00482,Celecoxib
,18969115,recoveries,"The proposed procedure was successfully applied for the determination of the drug in capsules and human serum with mean recoveries of 101.5+/-0.6 and 98.8+/-1.1%, respectively.",Adsorptive stripping voltammetric determination of the anti-inflammatory drug celecoxib in pharmaceutical formulation and human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969115/),%,98.8,79597,DB00482,Celecoxib
,18969115,detection,A detection and quantitation limits of 1.0 x 10(-9) M (0.4 ng ml(-1)) and 4.7 x 10(-9) M (1.3 ng ml(-1)) were achieved for the determination of the drug in human serum.,Adsorptive stripping voltammetric determination of the anti-inflammatory drug celecoxib in pharmaceutical formulation and human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969115/),M,1.0 x 10(-9),79598,DB00482,Celecoxib
,18969115,quantitation,A detection and quantitation limits of 1.0 x 10(-9) M (0.4 ng ml(-1)) and 4.7 x 10(-9) M (1.3 ng ml(-1)) were achieved for the determination of the drug in human serum.,Adsorptive stripping voltammetric determination of the anti-inflammatory drug celecoxib in pharmaceutical formulation and human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969115/),[ng] / [ml],0.4,79599,DB00482,Celecoxib
,18969115,quantitation,A detection and quantitation limits of 1.0 x 10(-9) M (0.4 ng ml(-1)) and 4.7 x 10(-9) M (1.3 ng ml(-1)) were achieved for the determination of the drug in human serum.,Adsorptive stripping voltammetric determination of the anti-inflammatory drug celecoxib in pharmaceutical formulation and human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969115/),M,4.7 x 10(-9),79600,DB00482,Celecoxib
,18969115,quantitation,A detection and quantitation limits of 1.0 x 10(-9) M (0.4 ng ml(-1)) and 4.7 x 10(-9) M (1.3 ng ml(-1)) were achieved for the determination of the drug in human serum.,Adsorptive stripping voltammetric determination of the anti-inflammatory drug celecoxib in pharmaceutical formulation and human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969115/),[ng] / [ml],1.3,79601,DB00482,Celecoxib
,32751591,molar substitution ratio,"The successful introduction of PEG 2000 or 5000 to Eudragit L100 (EL) was confirmed via proton nuclear magnetic resonance analysis of which calculated molar substitution ratio of PEG to EL was 36.0 or 36.7, respectively.",Preparation and Evaluation of Eudragit L100-PEG Proliponiosomes for Enhanced Oral Delivery of Celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32751591/),,36.0,82949,DB00482,Celecoxib
,32751591,molar substitution ratio,"The successful introduction of PEG 2000 or 5000 to Eudragit L100 (EL) was confirmed via proton nuclear magnetic resonance analysis of which calculated molar substitution ratio of PEG to EL was 36.0 or 36.7, respectively.",Preparation and Evaluation of Eudragit L100-PEG Proliponiosomes for Enhanced Oral Delivery of Celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32751591/),,36.7,82950,DB00482,Celecoxib
,28947805,T1/2el,"In contrast to celecoxib (T1/2el = 0.88 h) and meloxicam (T1/2el = 0.90 h), mavacoxib has a prolonged elimination half-life (T1/2el = 135 h) following oral administration of a commercial formulation (CF).","Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947805/),h,0.88,84290,DB00482,Celecoxib
,28947805,T1/2el,"In contrast to celecoxib (T1/2el = 0.88 h) and meloxicam (T1/2el = 0.90 h), mavacoxib has a prolonged elimination half-life (T1/2el = 135 h) following oral administration of a commercial formulation (CF).","Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947805/),h,0.90,84291,DB00482,Celecoxib
,28947805,elimination half-life (T1/2el,"In contrast to celecoxib (T1/2el = 0.88 h) and meloxicam (T1/2el = 0.90 h), mavacoxib has a prolonged elimination half-life (T1/2el = 135 h) following oral administration of a commercial formulation (CF).","Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947805/),h,135,84292,DB00482,Celecoxib
,28947805,F%,"High to complete oral absorption was observed following oral administration of celecoxib (F% = 56-110%) and mavacoxib (F% = 111-113%), CF and standard solutions, respectively.","Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947805/),%,56-110,84293,DB00482,Celecoxib
,28947805,F%,"High to complete oral absorption was observed following oral administration of celecoxib (F% = 56-110%) and mavacoxib (F% = 111-113%), CF and standard solutions, respectively.","Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947805/),%,111-113,84294,DB00482,Celecoxib
,28947805,F%,"In contrast, the F% of meloxicam was low (F% = 11%).","Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947805/),%,11,84295,DB00482,Celecoxib
,25621435,flow rate,"Chromatographic separation was carried on Acquity BEH™ C18 column (50mm×2.1mm, 1.7μm) using an isocratic mobile phase of acetonitrile: 10mM ammonium acetate (80:20, v/v), at a flow rate of 0.250mL/min.",A validated UPLC-MS/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25621435/),[ml] / [min],0.250,86531,DB00482,Celecoxib
,25621435,total run time,"Both pomalidomide and IS were eluted at 0.66±0.03 and 0.80±0.03min, respectively, with a total run time of 1.5min only.",A validated UPLC-MS/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25621435/),min,1.5,86532,DB00482,Celecoxib
,25621435,m,"The precursor to product ion transitions of m/z 272.01→160.89 for pomalidomide and m/z 380.08→316.01 for IS were used to quantify them respectively, multiple reaction monitoring mode.",A validated UPLC-MS/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25621435/),,272.01,86533,DB00482,Celecoxib
,12426512,Peak plasma concentrations,Peak plasma concentrations (1234 +/- 528 microg/L) were achieved 3 hours after drug administration.,Single-dose and steady-state pharmacokinetics of celecoxib in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426512/),[μg] / [l],1234,88957,DB00482,Celecoxib
,12426512,area under the celecoxib plasma concentration-time curve,"The area under the celecoxib plasma concentration-time curve was 7709 +/- 3176 microg/L x h, the elimination half-life (t(1/2)) was 3.7 +/- 1.1 hours, the apparent volume of distribution was 7.9 +/- 7.8 L/kg, and the lower oral clearance of the drug was 1.4 +/- 1.0 L x h(-1) x kg(-1).",Single-dose and steady-state pharmacokinetics of celecoxib in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426512/),[μg] / [h·l],7709,88958,DB00482,Celecoxib
,12426512,elimination half-life (t(1/2)),"The area under the celecoxib plasma concentration-time curve was 7709 +/- 3176 microg/L x h, the elimination half-life (t(1/2)) was 3.7 +/- 1.1 hours, the apparent volume of distribution was 7.9 +/- 7.8 L/kg, and the lower oral clearance of the drug was 1.4 +/- 1.0 L x h(-1) x kg(-1).",Single-dose and steady-state pharmacokinetics of celecoxib in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426512/),h,3.7,88959,DB00482,Celecoxib
,12426512,apparent volume of distribution,"The area under the celecoxib plasma concentration-time curve was 7709 +/- 3176 microg/L x h, the elimination half-life (t(1/2)) was 3.7 +/- 1.1 hours, the apparent volume of distribution was 7.9 +/- 7.8 L/kg, and the lower oral clearance of the drug was 1.4 +/- 1.0 L x h(-1) x kg(-1).",Single-dose and steady-state pharmacokinetics of celecoxib in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426512/),[l] / [kg],7.9,88960,DB00482,Celecoxib
,11522069,retention time,The retention time of rofecoxib was 1.2 min.,Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522069/),min,1.2,91753,DB00482,Celecoxib
,11522069,tmax,"The pharmacokinetic characteristics (mean+/-SD) were tmax: 2.4+/-1.0 h, Cmax: 147+/-34 microg/l, AUCinfinity: 2038+/-581 microg h/l and t 1/2: 11.3+/-2.1 h.",Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522069/),h,2.4,91754,DB00482,Celecoxib
,11522069,Cmax,"The pharmacokinetic characteristics (mean+/-SD) were tmax: 2.4+/-1.0 h, Cmax: 147+/-34 microg/l, AUCinfinity: 2038+/-581 microg h/l and t 1/2: 11.3+/-2.1 h.",Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522069/),[μg] / [l],147,91755,DB00482,Celecoxib
,11522069,AUCinfinity,"The pharmacokinetic characteristics (mean+/-SD) were tmax: 2.4+/-1.0 h, Cmax: 147+/-34 microg/l, AUCinfinity: 2038+/-581 microg h/l and t 1/2: 11.3+/-2.1 h.",Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522069/),[h·μg] / [l],2038,91756,DB00482,Celecoxib
,11522069,t 1/2,"The pharmacokinetic characteristics (mean+/-SD) were tmax: 2.4+/-1.0 h, Cmax: 147+/-34 microg/l, AUCinfinity: 2038+/-581 microg h/l and t 1/2: 11.3+/-2.1 h.",Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522069/),h,11.3,91757,DB00482,Celecoxib
,25463193,maximum injection time,"Data acquisition was performed at 25,000 resolution with the automatic gain set to 1,000,000 and the maximum injection time of 100 ms.",Pharmacokinetics and metabolism study of firocoxib in camels after intravenous administration by using high-resolution bench-top orbitrap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25463193/),ms,100,94262,DB00482,Celecoxib
,25463193,extraction recoveries,"The mean extraction recoveries of firocoxib at three concentrations of 5, 25 and 75 ng/mL ranged from 92 to 104%.",Pharmacokinetics and metabolism study of firocoxib in camels after intravenous administration by using high-resolution bench-top orbitrap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25463193/),%,92 to 104,94263,DB00482,Celecoxib
,25463193,terminal elimination half-life (t₁/₂β),"The results obtained (mean ± SD) were as follows: the terminal elimination half-life (t₁/₂β) was 5.75 ± 2.26 h, and total body clearance (ClT) was 354.1 ± 82.6 mL/kg/h.",Pharmacokinetics and metabolism study of firocoxib in camels after intravenous administration by using high-resolution bench-top orbitrap mass spectrometry. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25463193/),h,5.75,94264,DB00482,Celecoxib
,25463193,total body clearance (ClT),"The results obtained (mean ± SD) were as follows: the terminal elimination half-life (t₁/₂β) was 5.75 ± 2.26 h, and total body clearance (ClT) was 354.1 ± 82.6 mL/kg/h.",Pharmacokinetics and metabolism study of firocoxib in camels after intravenous administration by using high-resolution bench-top orbitrap mass spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25463193/),[ml] / [h·kg],354.1,94265,DB00482,Celecoxib
,25463193,volume of distribution at steady state (VSS),The volume of distribution at steady state (VSS) was 2344.4 ± 238.7 mL/kg.,Pharmacokinetics and metabolism study of firocoxib in camels after intravenous administration by using high-resolution bench-top orbitrap mass spectrometry. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25463193/),[ml] / [kg],2344.4,94266,DB00482,Celecoxib
,25463193,m/,One metabolite of firocoxib was tentatively identified as desalkyl firocoxib (m/z 283).,Pharmacokinetics and metabolism study of firocoxib in camels after intravenous administration by using high-resolution bench-top orbitrap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25463193/),,283,94267,DB00482,Celecoxib
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,0.31,94872,DB00482,Celecoxib
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,2.2,94873,DB00482,Celecoxib
,17920584,ID(50),"In an adjuvant-induced arthritic model in rats, CS-706 suppressed foot swelling prophylactically with an ID(50) of 0.10 mg/kg/day, and decreased foot swelling in the established arthritis therapeutically in a dose range of 0.040 to 1.0 mg/kg/day.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),[mg] / [d·kg],0.10,94874,DB00482,Celecoxib
,20153385,particle size,"The particle size and entrapment efficiency of the Cxb-NLC formulation were 217+/-20nm and >90%, respectively.","Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20153385/),nm,217,103904,DB00482,Celecoxib
,20153385,entrapment efficiency,"The particle size and entrapment efficiency of the Cxb-NLC formulation were 217+/-20nm and >90%, respectively.","Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20153385/),%,90,103905,DB00482,Celecoxib
,20153385,FPF,"The Cxb-NLC released the drug in controlled fashion, and in-vitro aerosolization of Cxb-NLC formulation showed an FPF of 75.6+/-4.6%, MMAD of 1.6+/-0.13microm and a GSD of 1.2+/-0.21.","Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20153385/),%,75.6,103906,DB00482,Celecoxib
,20153385,systemic clearance,The systemic clearance of Cxb-NLC was slower (0.93l/h) compared to the Cxb-Soln (20.03l/h).,"Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20153385/),[l] / [h],0.93,103907,DB00482,Celecoxib
,20153385,systemic clearance,The systemic clearance of Cxb-NLC was slower (0.93l/h) compared to the Cxb-Soln (20.03l/h).,"Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20153385/),[l] / [h],20.03,103908,DB00482,Celecoxib
,16013036,flow rate,The chromatographic separation was achieved by gradient elution consisting of 0.05 M formic acid (pH 3)-acetonitrile-methanol-water at a flow rate of 1.0 mL/min.,"Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),[ml] / [min],1.0,105998,DB00482,Celecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,15.63,105999,DB00482,Celecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,17.20,106000,DB00482,Celecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,21.66,106001,DB00482,Celecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,24.95,106002,DB00482,Celecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,26.27,106003,DB00482,Celecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,30.24,106004,DB00482,Celecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,32.22,106005,DB00482,Celecoxib
>,16013036,Absolute recovery,Absolute recovery was >83% from human plasma for all the analytes and IS.,"Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),%,83,106006,DB00482,Celecoxib
≈,31150807,en,"Reconstitution of CXBPLs with gentle shaking by hand generated CXB-loaded liposomes with nano-sized mean diameter, negative zeta potential, vesicular-shaped morphology, and high CXB entrapment efficiency (≈84.7%).",Preparation and evaluation of celecoxib-loaded proliposomes with high lipid content. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150807/),,84.7,106572,DB00482,Celecoxib
,11816012,retention time,The retention time of celecoxib was 2.3 min.,Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),min,2.3,112197,DB00482,Celecoxib
,11816012,t(max),"Pharmacokinetic characteristics (mean +/- SD) of extensive metabolizers (EM) were t(max) 2.9+/-1.2h, c(max) 842+/-280 microg/L, AUC(infinity) 6246+/-2147 microg h/L and t(1/2) 7.8+/-2.7h.",Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),h,2.9,112198,DB00482,Celecoxib
,11816012,c(max),"Pharmacokinetic characteristics (mean +/- SD) of extensive metabolizers (EM) were t(max) 2.9+/-1.2h, c(max) 842+/-280 microg/L, AUC(infinity) 6246+/-2147 microg h/L and t(1/2) 7.8+/-2.7h.",Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),[μg] / [l],842,112199,DB00482,Celecoxib
,11816012,AUC(infinity),"Pharmacokinetic characteristics (mean +/- SD) of extensive metabolizers (EM) were t(max) 2.9+/-1.2h, c(max) 842+/-280 microg/L, AUC(infinity) 6246+/-2147 microg h/L and t(1/2) 7.8+/-2.7h.",Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),[h·μg] / [l],6246,112200,DB00482,Celecoxib
,11816012,t(1/2),"Pharmacokinetic characteristics (mean +/- SD) of extensive metabolizers (EM) were t(max) 2.9+/-1.2h, c(max) 842+/-280 microg/L, AUC(infinity) 6246+/-2147 microg h/L and t(1/2) 7.8+/-2.7h.",Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),h,7.8,112201,DB00482,Celecoxib
,11816012,area under the curve (AUC(infinity)),The area under the curve (AUC(infinity)) for the PM was 12561 microg h/L.,Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),[h·μg] / [l],12561,112202,DB00482,Celecoxib
,11816012,half life,"However, we found no noticeable increase in half life in the PM (11.5 h) after a single dose of celecoxib.",Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),h,11.5,112203,DB00482,Celecoxib
,23543607,relative bioavailability,The mean relative bioavailability of MC1 formulation to plain celecoxib was 157.55±20.18%.,Influence of microcrystal formulation on in vivo absorption of celecoxib in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23543607/),%,157.55,112591,DB00482,Celecoxib
,16176646,flow rate,"UV detection is performed at 254 nm, and the flow rate is maintained at 1.0 mL/min.",Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176646/),[ml] / [min],1.0,113197,DB00482,Celecoxib
,28159531,flow rate,"Waters XTerra RP HPLC column (4.6×100mm, 5μm) with mobile phase consisting of acetonitrile and 10mM ammonium acetate (pH-6.0) in the ratio 85:15 (v/v) at a flow rate of 1mL/min was used for the chromatographic separation.",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),[ml] / [min],1,113708,DB00482,Celecoxib
,28159531,m/,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,420.17,113709,DB00482,Celecoxib
,28159531,m/z,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,489.59,113710,DB00482,Celecoxib
,28159531,m/z,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,350.12,113711,DB00482,Celecoxib
,28159531,m/z,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,380.08,113712,DB00482,Celecoxib
,28159531,m/z,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,316.31,113713,DB00482,Celecoxib
,28159531,total run time,A total run time of 3min and LLOQ was found to be 5ng/mL for both PIT and GLI.,A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),min,3,113714,DB00482,Celecoxib
,28159531,total run time,A total run time of 3min and LLOQ was found to be 5ng/mL for both PIT and GLI.,A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),[ng] / [ml],5,113715,DB00482,Celecoxib
,23008811,flow rate,"The analytes were separated on a reverse-phase C(18) column (50mm×4.6mm i.d., 3μ) using methanol: 2 mM ammonium acetate buffer, and pH 4.0 as the mobile phase at a flow rate 0.8 mL/min.","Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23008811/),[ml] / [min],0.8,114474,DB00482,Celecoxib
,22771234,flow rate,"After one-step liquid-liquid extraction (LLE) using methyl tert-butyl ether (MTBE), celecoxib and atorvastatin (internal standard, IS) were eluted on a Luna HILIC column with an isocratic mobile phase, consisting of 10mM ammonium formate buffer (adjusted to pH 3.0 with formic acid):methanol (5:95, v/v) at a flow rate of 0.2 mL/min.",Development of simple and rapid LC-MS/MS method for determination of celecoxib in human plasma and its application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771234/),[ml] / [min],0.2,115777,DB00482,Celecoxib
>,22771234,S/N,The achieved lower limit of quantitation (LLOQ) was 10 ng/mL (S/N>10) and the standard calibration curve for celecoxib was linear (correlation coefficients were >0.9995) over the studied concentration range (10-2000 ng/mL).,Development of simple and rapid LC-MS/MS method for determination of celecoxib in human plasma and its application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771234/),,10,115778,DB00482,Celecoxib
<,22771234,run time,The chromatographic run time for each plasma sample was <2 min.,Development of simple and rapid LC-MS/MS method for determination of celecoxib in human plasma and its application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771234/),min,2,115779,DB00482,Celecoxib
,28810061,maximum plasma concentration,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),[ng] / [ml],263,118155,DB00482,Celecoxib
,28810061,maximum plasma concentration,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),[ng] / [ml],346,118156,DB00482,Celecoxib
,28810061,maximum plasma concentration,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),[ng] / [ml],349,118157,DB00482,Celecoxib
,28810061,cumulative area under the plasma concentration-time curve,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),[h·ng] / [ml],3039,118158,DB00482,Celecoxib
,28810061,cumulative area under the plasma concentration-time curve,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),[h·ng] / [ml],2979,118159,DB00482,Celecoxib
,28810061,cumulative area under the plasma concentration-time curve,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),[h·ng] / [ml],3119,118160,DB00482,Celecoxib
,28810061,time to maximum plasma concentration,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),h,2.7,118161,DB00482,Celecoxib
,28810061,time to maximum plasma concentration,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),h,1.8,118162,DB00482,Celecoxib
,28888220,maximum plasma concentration (Cmax ),"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),[ng] / [ml],551,121331,DB00482,Celecoxib
,28888220,maximum plasma concentration (Cmax ),"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),[ng] / [ml],632,121332,DB00482,Celecoxib
,28888220,maximum plasma concentration (Cmax ),"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),[ng] / [ml],661,121333,DB00482,Celecoxib
,28888220,area under the plasma concentration-time curve over the dosing interval at steady state,"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),[h·ng] / [ml],4796,121334,DB00482,Celecoxib
,28888220,area under the plasma concentration-time curve over the dosing interval at steady state,"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),[h·ng] / [ml],4990,121335,DB00482,Celecoxib
,28888220,area under the plasma concentration-time curve over the dosing interval at steady state,"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),[h·ng] / [ml],5284,121336,DB00482,Celecoxib
,28888220,time to Cmax at steady state,"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),h,3.0,121337,DB00482,Celecoxib
,28888220,time to Cmax at steady state,"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),h,2.0,121338,DB00482,Celecoxib
,21036913,IC(50),"KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC(50) values 50-400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC(50) >15,000 nM).","Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),nM,50-400,122850,DB00482,Celecoxib
>,21036913,IC(50),"KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC(50) values 50-400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC(50) >15,000 nM).","Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),nM,"15,000",122851,DB00482,Celecoxib
≤,21036913,minimal effective dose,KLYP961 also attenuated capsaicin-induced thermal allodynia in rhesus primates in a dose-related manner with a minimal effective dose (≤ 10 mg/kg p.o.) and a greater potency than gabapentin.,"Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),mg,10,122852,DB00482,Celecoxib
,18358504,IC(50),RIAA inhibited LPS-stimulated PGE(2) formation with >200-fold selectivity of COX-2 (IC(50)=1.3 microg/ml) over COX-1 (IC(50)>289 microg/ml).,"Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],1.3,123772,DB00482,Celecoxib
>,18358504,IC(50),RIAA inhibited LPS-stimulated PGE(2) formation with >200-fold selectivity of COX-2 (IC(50)=1.3 microg/ml) over COX-1 (IC(50)>289 microg/ml).,"Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],289,123773,DB00482,Celecoxib
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],21,123774,DB00482,Celecoxib
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],0.024,123775,DB00482,Celecoxib
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],0.52,123776,DB00482,Celecoxib
,18358504,IC(50),"In support, we found RIAA showed minimal PGE(2) inhibition (IC(50)=21mug/ml) relative to celecoxib (IC(50)=0.024 microg/ml), aspirin (IC(50)=0.52 microg/ml) or ibuprofen (IC(50)=0.57 microg/ml) in the AGS gastric mucosal model, where COX-1 and -2 are expressed constitutively.","Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18358504/),[μg] / [ml],0.57,123777,DB00482,Celecoxib
,15577219,relative bioavailability,The relative bioavailability of the SMEDDS formulation to the conventional capsule was 132%.,Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15577219/),%,132,130616,DB00482,Celecoxib
,18287342,survival time,"With 31 of 35 patients deceased, estimated median survival time for all patients was 12 months (+EIASD, 11.5 months; - EIASD, 16 months; p = 0.11).",Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18287342/),month,12,137791,DB00482,Celecoxib
,18287342,survival time,"With 31 of 35 patients deceased, estimated median survival time for all patients was 12 months (+EIASD, 11.5 months; - EIASD, 16 months; p = 0.11).",Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18287342/),month,11.5,137792,DB00482,Celecoxib
,18287342,survival time,"With 31 of 35 patients deceased, estimated median survival time for all patients was 12 months (+EIASD, 11.5 months; - EIASD, 16 months; p = 0.11).",Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18287342/),month,16,137793,DB00482,Celecoxib
,32832543,flow rate,"The plasma was precipitated by acetonitrile, and the two analytes were separated on an Acquity UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 μm); the mobile phase was acetonitrile and 0.1% formic acid with gradient mode, and the flow rate was 0.4 mL/min.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ml] / [min],0.4,138190,DB00482,Celecoxib
,32832543,m/,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,369.1,138191,DB00482,Celecoxib
,32832543,m/z,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,313.0,138192,DB00482,Celecoxib
,32832543,m/z,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,118.0,138193,DB00482,Celecoxib
,32832543,m/z,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,380.0,138194,DB00482,Celecoxib
,32832543,m/z,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,316.0,138195,DB00482,Celecoxib
,32832543,C max,"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ng] / [ml],2148.59,138196,DB00482,Celecoxib
,32832543,C max,"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ng] / [ml],2100.49,138197,DB00482,Celecoxib
,32832543,t 1/2,"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,0.85,138198,DB00482,Celecoxib
,32832543,AUC(0-t),"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[h·ng] / [ml],2429.96,138199,DB00482,Celecoxib
,32832543,AUC(0-t),"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[h·ng] / [ml],2506.38,138200,DB00482,Celecoxib
,32832543,C max,"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ng] / [ml],2059.15,138201,DB00482,Celecoxib
,32832543,C max,"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ng] / [ml],2837.39,138202,DB00482,Celecoxib
,32832543,t 1/2,"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,2.44,138203,DB00482,Celecoxib
,32832543,t 1/2,"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,2.91,138204,DB00482,Celecoxib
,32832543,AUC(0-t),"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[h·ng] / [ml],4971.61,138205,DB00482,Celecoxib
,32832543,AUC(0-t),"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[h·ng] / [ml],6770.65,138206,DB00482,Celecoxib
,32832543,t 1/2,"There was no significant change in the pharmacokinetics of parecoxib in groups A and B. C max and AUC(0 - ∞) of valdecoxib in group A were 37.79% and 36.19% higher than those in group B, respectively, and t 1/2 was increased from 2.44 h to 2.91 h.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,2.44,138207,DB00482,Celecoxib
,32832543,t 1/2,"There was no significant change in the pharmacokinetics of parecoxib in groups A and B. C max and AUC(0 - ∞) of valdecoxib in group A were 37.79% and 36.19% higher than those in group B, respectively, and t 1/2 was increased from 2.44 h to 2.91 h.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,2.91,138208,DB00482,Celecoxib
,10681375,total percentage of administered radioactive dose recovered,"The total percentage of administered radioactive dose recovered was 84.8 +/- 4.9%, with 27.1 +/- 2.2% in the urine and 57.6 +/- 7.3% in the feces.",Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681375/),%,84.8,140944,DB00482,Celecoxib
,10681375,total percentage of administered radioactive dose recovered,"The total percentage of administered radioactive dose recovered was 84.8 +/- 4.9%, with 27.1 +/- 2.2% in the urine and 57.6 +/- 7.3% in the feces.",Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681375/),%,27.1,140945,DB00482,Celecoxib
,10681375,total percentage of administered radioactive dose recovered,"The total percentage of administered radioactive dose recovered was 84.8 +/- 4.9%, with 27.1 +/- 2.2% in the urine and 57.6 +/- 7.3% in the feces.",Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681375/),%,57.6,140946,DB00482,Celecoxib
,10701700,fraction of bound drug,The fraction of bound drug in the volunteers was constant (97.4 +/- 0.1%) at total celecoxib plasma concentrations ranging from 0.01 to 4.02 microg/mL.,"Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701700/),%,97.4,141822,DB00482,Celecoxib
up,10701700,plasma protein binding,"The ex vivo plasma protein binding of celecoxib in the animals was concentration-independent up to approximately 12, 8 and 10 microg/mL for mouse, rat and dog, respectively.","Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701700/),[μg] / [ml],12,141823,DB00482,Celecoxib
,10701700,plasma protein binding,"The ex vivo plasma protein binding of celecoxib in the animals was concentration-independent up to approximately 12, 8 and 10 microg/mL for mouse, rat and dog, respectively.","Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701700/),[μg] / [ml],8,141824,DB00482,Celecoxib
,10701700,plasma protein binding,"The ex vivo plasma protein binding of celecoxib in the animals was concentration-independent up to approximately 12, 8 and 10 microg/mL for mouse, rat and dog, respectively.","Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701700/),[μg] / [ml],10,141825,DB00482,Celecoxib
,10701700,plasma protein binding,"The plasma protein binding of celecoxib after a single oral dose of 10 and 300 mg/kg to mice was 98.3 +/- 0.2%, of 1 and 400 mg/kg to rats was 98.3 +/- 0.2% and of 1 and 100 mg/kg to dogs was 98.5 +/- 0.1%.","Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701700/),%,98.3,141826,DB00482,Celecoxib
,10701700,plasma protein binding,"The plasma protein binding of celecoxib after a single oral dose of 10 and 300 mg/kg to mice was 98.3 +/- 0.2%, of 1 and 400 mg/kg to rats was 98.3 +/- 0.2% and of 1 and 100 mg/kg to dogs was 98.5 +/- 0.1%.","Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701700/),%,98.5,141827,DB00482,Celecoxib
,24085777,Overall histologic response rate,"Overall histologic response rate was 63% (complete response, 43%; partial response, 14%; stable disease, 29%; and disease progression, 14%).",Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),%,63,146992,DB00482,Celecoxib
,24085777,Overall histologic response rate,"Overall histologic response rate was 63% (complete response, 43%; partial response, 14%; stable disease, 29%; and disease progression, 14%).",Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),%,43,146993,DB00482,Celecoxib
,24085777,Overall histologic response rate,"Overall histologic response rate was 63% (complete response, 43%; partial response, 14%; stable disease, 29%; and disease progression, 14%).",Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),%,14,146994,DB00482,Celecoxib
,24085777,time to progression,"With median follow-up of 36 months, mean time to progression to higher-grade dysplasia or carcinoma was 25.4 months.",Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),month,25.4,146995,DB00482,Celecoxib
,24085777,V/F,Larger average erlotinib V/F (approximately 308 L) and CL/F (8.3 L/h) compared with previous studies may be related to relatively large average bodyweights.,Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),l,308,146996,DB00482,Celecoxib
,24085777,CL/F,Larger average erlotinib V/F (approximately 308 L) and CL/F (8.3 L/h) compared with previous studies may be related to relatively large average bodyweights.,Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),[l] / [h],8.3,146997,DB00482,Celecoxib
,24085777,t1/2,Average erlotinib t1/2 was 25.6 hours.,Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085777/),h,25.6,146998,DB00482,Celecoxib
,34167827,Cmax,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[ng] / [ml],259,146999,DB00482,Celecoxib
,34167827,Cmax,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[ng] / [ml],318,147000,DB00482,Celecoxib
,34167827,Cmax,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[ng] / [ml],165,147001,DB00482,Celecoxib
,34167827,AUC0-T,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[h·ng] / [ml],1930,147002,DB00482,Celecoxib
,34167827,AUC0-T,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[h·ng] / [ml],2348,147003,DB00482,Celecoxib
,34167827,AUC0-T,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[h·ng] / [ml],1929,147004,DB00482,Celecoxib
,34167827,Tmax,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,1.5,147005,DB00482,Celecoxib
,34167827,Tmax,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,3.0,147006,DB00482,Celecoxib
,34167827,Tmax,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,2.5,147007,DB00482,Celecoxib
,34167827,Cmax,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[ng] / [ml],305/78,147008,DB00482,Celecoxib
,34167827,Cmax,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[ng] / [ml],312/78,147009,DB00482,Celecoxib
,34167827,AUC0-T,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[h·ng] / [ml],2507/846,147010,DB00482,Celecoxib
,34167827,AUC0-T,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[h·ng] / [ml],2709/965,147011,DB00482,Celecoxib
,34167827,AUC0-T,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[h·ng] / [ml],2888/1010,147012,DB00482,Celecoxib
,34167827,Tmax,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,3.0,147013,DB00482,Celecoxib
,34167827,Tmax,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,2.0,147014,DB00482,Celecoxib
,34167827,Tmax,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,1.9/,147015,DB00482,Celecoxib
,34167827,Tmax,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,2.5,147016,DB00482,Celecoxib
,32214797,mass,"The mass transfer pairs were m/z 368.97→119.01 for parecoxib, m/z 312.89→118.02 for valdecoxib, and m/z 379.98→316.02 for celecoxib (internal standard, IS).",Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32214797/),,368.97,147212,DB00482,Celecoxib
,32214797,m/z,"The mass transfer pairs were m/z 368.97→119.01 for parecoxib, m/z 312.89→118.02 for valdecoxib, and m/z 379.98→316.02 for celecoxib (internal standard, IS).",Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32214797/),,368.97,147213,DB00482,Celecoxib
,32214797,m/z,"The mass transfer pairs were m/z 368.97→119.01 for parecoxib, m/z 312.89→118.02 for valdecoxib, and m/z 379.98→316.02 for celecoxib (internal standard, IS).",Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32214797/),,312.89,147214,DB00482,Celecoxib
,32214797,m/z,"The mass transfer pairs were m/z 368.97→119.01 for parecoxib, m/z 312.89→118.02 for valdecoxib, and m/z 379.98→316.02 for celecoxib (internal standard, IS).",Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32214797/),,118.02,147215,DB00482,Celecoxib
,32214797,m/z,"The mass transfer pairs were m/z 368.97→119.01 for parecoxib, m/z 312.89→118.02 for valdecoxib, and m/z 379.98→316.02 for celecoxib (internal standard, IS).",Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32214797/),,379.98,147216,DB00482,Celecoxib
greater,32214797,recovery,The recovery of parecoxib and valdecoxib was greater than 82.54%.,Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32214797/),%,82.54,147217,DB00482,Celecoxib
,30075312,half-life in blood,Celecoxib half-life in blood increased from 5 h for the bolus injection of celecoxib to more than 10 days for the slowest releasing gel formulation.,In vivo pharmacokinetics of celecoxib loaded endcapped PCLA-PEG-PCLA thermogels in rats after subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30075312/),h,5,147978,DB00482,Celecoxib
more,30075312,half-life in blood,Celecoxib half-life in blood increased from 5 h for the bolus injection of celecoxib to more than 10 days for the slowest releasing gel formulation.,In vivo pharmacokinetics of celecoxib loaded endcapped PCLA-PEG-PCLA thermogels in rats after subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30075312/),d,10,147979,DB00482,Celecoxib
,27789031,shelf lives,"Gels containing CS-NPs and PCL-NPs were selected for an ocular pharmacokinetics study using Sprague-Dawley rats due to their high stability and long shelf lives (24.56 and 33.76 months, respectively).",Stability and Ocular Pharmacokinetics of Celecoxib-Loaded Nanoparticles Topical Ophthalmic Formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789031/),month,24.56,149661,DB00482,Celecoxib
,27789031,shelf lives,"Gels containing CS-NPs and PCL-NPs were selected for an ocular pharmacokinetics study using Sprague-Dawley rats due to their high stability and long shelf lives (24.56 and 33.76 months, respectively).",Stability and Ocular Pharmacokinetics of Celecoxib-Loaded Nanoparticles Topical Ophthalmic Formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789031/),month,33.76,149662,DB00482,Celecoxib
,23852645,effective permeability (Peff),The effective permeability (Peff) of CXB in the control solution (2.5 v/v% Tween 20-containing PBS) was 6.39 × 10(-5) cm/s.,In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23852645/),[cm] / [s],6.39 × 10(-5),153043,DB00482,Celecoxib
,23852645,relative bioavailabilities,"The relative bioavailabilities of SEDDS and S-SEDDS were 263 and 355 %, respectively, compared to the CXB suspension as a reference.",In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23852645/),%,263,153044,DB00482,Celecoxib
,23852645,relative bioavailabilities,"The relative bioavailabilities of SEDDS and S-SEDDS were 263 and 355 %, respectively, compared to the CXB suspension as a reference.",In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23852645/),%,355,153045,DB00482,Celecoxib
,18197403,K(i) (inhibitor constant),Celecoxib was found to be a moderately potent competitive inhibitor of CYP1A2 in vitro with a K(i) (inhibitor constant) of 25.4 microM.,Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197403/),μM,25.4,155529,DB00482,Celecoxib
,11754119,run time,The chromatographic run time was 4.5 min and the weighted (1/x) calibration curve was linear in the range 10.0-2000 ng x ml(-1).,Quantification of nimesulide in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11754119/),min,4.5,156642,DB00482,Celecoxib
,18613981,oral bioavailability,"It is a highly lipophilic, poorly soluble drug with oral bioavailability of around 40% (Capsule).",Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613981/),%,40,156738,DB00482,Celecoxib
,18613981,activation energy,The significant decrease in activation energy (2.373 kcal/mol) for celecoxib permeation across rat skin indicated that the stratum corneum lipid bilayers were significantly disrupted (p < 0.05).,Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613981/),[kcal] / [mol],2.373,156739,DB00482,Celecoxib
,16149679,peak concentration (Cmax),"Following a 200 mg celecoxib oral administration, the drug was absorbed into the systemic circulation and reach maximum concentration (Tmax) within 2.50 +/- 1.22 hrs by average with the mean peak concentration (Cmax) of 686.83 +/- 211.35 ng/ml.",Clinical pharmacokinetic of celecoxib in healthy Thai volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16149679/),[ng] / [ml],686.83,156962,DB00482,Celecoxib
,16149679,"area under the curve, AUC","The extent of absorption (area under the curve, AUC) was approximately 5157.12 +/- 1499.46 and 5911.48 +/- 1363.51 ng hr/ml for AUC(0-->t) and AUC(0-->infinity) respectively.",Clinical pharmacokinetic of celecoxib in healthy Thai volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16149679/),[h·ng] / [ml],5157.12,156963,DB00482,Celecoxib
,16149679,"area under the curve, AUC","The extent of absorption (area under the curve, AUC) was approximately 5157.12 +/- 1499.46 and 5911.48 +/- 1363.51 ng hr/ml for AUC(0-->t) and AUC(0-->infinity) respectively.",Clinical pharmacokinetic of celecoxib in healthy Thai volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16149679/),[h·ng] / [ml],5911.48,156964,DB00482,Celecoxib
,16149679,AUC(0-->t),"The extent of absorption (area under the curve, AUC) was approximately 5157.12 +/- 1499.46 and 5911.48 +/- 1363.51 ng hr/ml for AUC(0-->t) and AUC(0-->infinity) respectively.",Clinical pharmacokinetic of celecoxib in healthy Thai volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16149679/),[h·ng] / [ml],5911.48,156965,DB00482,Celecoxib
,16149679,apparent volume of distribution (Vd),The apparent volume of distribution (Vd) was found to be 458.93 +/- 323.28 L/hr.,Clinical pharmacokinetic of celecoxib in healthy Thai volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16149679/),[l] / [h],458.93,156966,DB00482,Celecoxib
,16149679,elimination half-life (t(1/2)),The elimination half-life (t(1/2)) of celecoxib appeared to be 8.79 +/- 5.49 hrs with the apparent clearance (CL) of 35.91 +/- 9.85 L.,Clinical pharmacokinetic of celecoxib in healthy Thai volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16149679/),h,8.79,156967,DB00482,Celecoxib
,16149679,apparent clearance (CL),The elimination half-life (t(1/2)) of celecoxib appeared to be 8.79 +/- 5.49 hrs with the apparent clearance (CL) of 35.91 +/- 9.85 L.,Clinical pharmacokinetic of celecoxib in healthy Thai volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16149679/),l,35.91,156968,DB00482,Celecoxib
,16149679,elimination rate constant,The elimination rate constant for celecoxib obtained from this present study was about 0.11 +/- 0.05 hr(-1).,Clinical pharmacokinetic of celecoxib in healthy Thai volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16149679/),1/[hr],0.11,156969,DB00482,Celecoxib
,12891223,area under the plasma concentration-time curve,"Celecoxib significantly increased the area under the plasma concentration-time curve of metoprolol from 271 to 414 micro g. h/L (64% +/- 57%, P <.001) and by more than 200% in 1 volunteer.",Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891223/),[h·μg] / [l],271 to 414,161598,DB00482,Celecoxib
,12891223,area under the plasma concentration-time curve from 0 to 24 hours,"After administration of celecoxib, the area under the plasma concentration-time curve from 0 to 24 hours of alpha-hydroxymetoprolol decreased significantly from 474 to 387 micro g. h/L (P <.01).",Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891223/),[h·μg] / [l],474,161599,DB00482,Celecoxib
,12891223,area under the plasma concentration-time curve from 0 to 24 hours,"After administration of celecoxib, the area under the plasma concentration-time curve from 0 to 24 hours of alpha-hydroxymetoprolol decreased significantly from 474 to 387 micro g. h/L (P <.01).",Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891223/),[h·μg] / [l],38,161600,DB00482,Celecoxib
,16995327,area under the plasma concentration-time curve,No effect of valdecoxib (20 mg/d) or rofecoxib (25 mg/d) were detected on the area under the plasma concentration-time curve of metoprolol (323 +/- 333 to 324 +/- 296 or 309 +/- 256 microg x h/l) or at a higher dose.,Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995327/),[h·μg] / [l],323,164280,DB00482,Celecoxib
,16995327,area under the plasma concentration-time curve,No effect of valdecoxib (20 mg/d) or rofecoxib (25 mg/d) were detected on the area under the plasma concentration-time curve of metoprolol (323 +/- 333 to 324 +/- 296 or 309 +/- 256 microg x h/l) or at a higher dose.,Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995327/),[h·μg] / [l],324,164281,DB00482,Celecoxib
,16995327,area under the plasma concentration-time curve,No effect of valdecoxib (20 mg/d) or rofecoxib (25 mg/d) were detected on the area under the plasma concentration-time curve of metoprolol (323 +/- 333 to 324 +/- 296 or 309 +/- 256 microg x h/l) or at a higher dose.,Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995327/),[h·μg] / [l],309,164282,DB00482,Celecoxib
,30458259,relative bioavailability (BA),The relative bioavailability (BA) of SD6 was significantly improved to 209.4% compared to that of Celebrex®.,Amorphous multi-system of celecoxib improves its anti-inflammatory activity in vitro and oral absorption in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30458259/),%,209.4,164822,DB00482,Celecoxib
,12603175,area under the concentration-time curve over the dosage interval (AUC(tau)),"For diclofenac, area under the concentration-time curve over the dosage interval (AUC(tau)) was larger in young subjects (3.2 +/- 1.0 mg * h/L) than in older individuals (2.4 +/- 0.4 mg * h/L; p < 0.05).",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),[h·mg] / [l],3.2,166277,DB00482,Celecoxib
,12603175,area under the concentration-time curve over the dosage interval (AUC(tau)),"For diclofenac, area under the concentration-time curve over the dosage interval (AUC(tau)) was larger in young subjects (3.2 +/- 1.0 mg * h/L) than in older individuals (2.4 +/- 0.4 mg * h/L; p < 0.05).",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),[h·mg] / [l],2.4,166278,DB00482,Celecoxib
,12603175,terminal half-life (t((1/2)Z)),"As the terminal half-life (t((1/2)Z)) was very similar in both groups (3.9 +/- 4.4 vs 3.5 +/- 3.3 hours), either less complete absorption in the elderly or their higher bodyweight could account for the difference.",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),h,3.9,166279,DB00482,Celecoxib
,12603175,terminal half-life (t((1/2)Z)),"As the terminal half-life (t((1/2)Z)) was very similar in both groups (3.9 +/- 4.4 vs 3.5 +/- 3.3 hours), either less complete absorption in the elderly or their higher bodyweight could account for the difference.",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),h,3.5,166280,DB00482,Celecoxib
,12603175,AUC(tau),"For celecoxib, AUC(tau) (5.8 +/- 1.7 vs 5.6 +/- 2.3 mg * h/L) and t((1/2)z) (11.8 +/- 8.7 vs 11.2 +/- 2.9 hours) were almost identical in young and older subjects.",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),[h·mg] / [l],5.8,166281,DB00482,Celecoxib
,12603175,AUC(tau),"For celecoxib, AUC(tau) (5.8 +/- 1.7 vs 5.6 +/- 2.3 mg * h/L) and t((1/2)z) (11.8 +/- 8.7 vs 11.2 +/- 2.9 hours) were almost identical in young and older subjects.",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),[h·mg] / [l],5.6,166282,DB00482,Celecoxib
,12603175,t((1/2)z),"For celecoxib, AUC(tau) (5.8 +/- 1.7 vs 5.6 +/- 2.3 mg * h/L) and t((1/2)z) (11.8 +/- 8.7 vs 11.2 +/- 2.9 hours) were almost identical in young and older subjects.",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),h,11.8,166283,DB00482,Celecoxib
,12603175,t((1/2)z),"For celecoxib, AUC(tau) (5.8 +/- 1.7 vs 5.6 +/- 2.3 mg * h/L) and t((1/2)z) (11.8 +/- 8.7 vs 11.2 +/- 2.9 hours) were almost identical in young and older subjects.",Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12603175/),h,11.2,166284,DB00482,Celecoxib
,17289892,Maximum tolerated dose,Maximum tolerated dose of irinotecan in FOLFIRI schedule with celecoxib is 200 mg/m2.,"Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17289892/),mg,200,166306,DB00482,Celecoxib
,26364711,percent drug release,"The percent drug release after 120min from CEL powder, S-SEDDS and SS-SEDDS with Sylysia 350 fcp, Aerosil 300 Pharma, Aerosil 200 Pharma and Aerosil R 972 Pharma was found to be 0.58%, 100%, 38.44%, 9.63%, 2.53% and 5.99%, respectively.",Role of solid carriers in pharmaceutical performance of solid supersaturable SEDDS of celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364711/),%,0.58,166735,DB00482,Celecoxib
,26364711,percent drug release,"The percent drug release after 120min from CEL powder, S-SEDDS and SS-SEDDS with Sylysia 350 fcp, Aerosil 300 Pharma, Aerosil 200 Pharma and Aerosil R 972 Pharma was found to be 0.58%, 100%, 38.44%, 9.63%, 2.53% and 5.99%, respectively.",Role of solid carriers in pharmaceutical performance of solid supersaturable SEDDS of celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364711/),%,100,166736,DB00482,Celecoxib
,26364711,percent drug release,"The percent drug release after 120min from CEL powder, S-SEDDS and SS-SEDDS with Sylysia 350 fcp, Aerosil 300 Pharma, Aerosil 200 Pharma and Aerosil R 972 Pharma was found to be 0.58%, 100%, 38.44%, 9.63%, 2.53% and 5.99%, respectively.",Role of solid carriers in pharmaceutical performance of solid supersaturable SEDDS of celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364711/),%,38.44,166737,DB00482,Celecoxib
,26364711,percent drug release,"The percent drug release after 120min from CEL powder, S-SEDDS and SS-SEDDS with Sylysia 350 fcp, Aerosil 300 Pharma, Aerosil 200 Pharma and Aerosil R 972 Pharma was found to be 0.58%, 100%, 38.44%, 9.63%, 2.53% and 5.99%, respectively.",Role of solid carriers in pharmaceutical performance of solid supersaturable SEDDS of celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364711/),%,9.63,166738,DB00482,Celecoxib
,26364711,percent drug release,"The percent drug release after 120min from CEL powder, S-SEDDS and SS-SEDDS with Sylysia 350 fcp, Aerosil 300 Pharma, Aerosil 200 Pharma and Aerosil R 972 Pharma was found to be 0.58%, 100%, 38.44%, 9.63%, 2.53% and 5.99%, respectively.",Role of solid carriers in pharmaceutical performance of solid supersaturable SEDDS of celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364711/),%,2.53,166739,DB00482,Celecoxib
,26364711,percent drug release,"The percent drug release after 120min from CEL powder, S-SEDDS and SS-SEDDS with Sylysia 350 fcp, Aerosil 300 Pharma, Aerosil 200 Pharma and Aerosil R 972 Pharma was found to be 0.58%, 100%, 38.44%, 9.63%, 2.53% and 5.99%, respectively.",Role of solid carriers in pharmaceutical performance of solid supersaturable SEDDS of celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26364711/),%,5.99,166740,DB00482,Celecoxib
,11888053,flow-rate,"Separation was achieved on a Prontosil C18 AQ column (150x3 mm I.D., 3-microm particle size) at a flow-rate of 0.35 ml/min using water-acetonitrile (40:60, v/v) as the mobile phase.",Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888053/),[ml] / [min],0.35,166966,DB00482,Celecoxib
,16599270,flow rate,The mobile phase was a mixture of acetonitrile:water acidified to pH 3.2 with orthophosphoric acid (OPA) (60:40) pumped at room temperature and a flow rate of 1 ml/min.,Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599270/),[ml] / [min],1,168944,DB00482,Celecoxib
,16599270,absolute recovery,"The mean absolute recovery value was about 90%, while the intra (n = 5) and inter (n = 5) assay variations were <18%.",Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599270/),%,90,168945,DB00482,Celecoxib
<,16599270,absolute recovery,"The mean absolute recovery value was about 90%, while the intra (n = 5) and inter (n = 5) assay variations were <18%.",Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599270/),%,18,168946,DB00482,Celecoxib
<,16599270,limit of detection,The limit of detection was < or = 10 ng/ml.,Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599270/),[ng] / [ml],10,168947,DB00482,Celecoxib
,18254155,recoveries,"The assay procedure involved extraction of rhein and IS from human plasma with acetonitrile, which yielded consistent recoveries of 36.01 and 65.85% for rhein and IS, respectively.",Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of rhein in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254155/),%,36.01,169669,DB00482,Celecoxib
,18254155,recoveries,"The assay procedure involved extraction of rhein and IS from human plasma with acetonitrile, which yielded consistent recoveries of 36.01 and 65.85% for rhein and IS, respectively.",Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of rhein in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254155/),%,65.85,169670,DB00482,Celecoxib
,18254155,total chromatographic run time,"The total chromatographic run time was 5.0 min and the elution of rhein and IS occurred at approximately 1.60 and 3.96 min, respectively.",Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of rhein in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254155/),min,5.0,169671,DB00482,Celecoxib
,20478302,Ki,[3H]methotrexate uptake into S2-hOAT3 cells was significantly inhibited by celecoxib in a concentration-dependent manner and the Ki value was 35.3 microM.,Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal cells and in rats in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20478302/),μM,35.3,173915,DB00482,Celecoxib
,20478302,maximum drug concentration (Cmax),"Celecoxib serum concentrations were increased by the increase in celecoxib dosage and the maximum drug concentration (Cmax) was 20.6 microM (celecoxib 200 mg/kg), which did not reach the Ki value obtained in the in vitro study.",Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal cells and in rats in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20478302/),μM,20.6,173916,DB00482,Celecoxib
below,17763056,Relative bioavailability,Relative bioavailability of celecoxib was below 20% in all cases and was probably the consequence of a slow in vivo release of celecoxib from microparticles or low wettability in the case of Celebrex and physical mixture.,Influence of polymers on the bioavailability of microencapsulated celecoxib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17763056/),%,20,177763,DB00482,Celecoxib
,30888074,maximum concentration,"After oral dosing, the drug reached a maximum concentration (mean ± SD) in blood of 1,088 ± 324 ng/ml in 4.58 hr.","Pharmacokinetics, metabolism and excretion of celecoxib, a selective cyclooxygenase-2 inhibitor, in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30888074/),[ng] / [ml],"1,088",179747,DB00482,Celecoxib
,30888074,elimination half-life,"The elimination half-life was 13.60 ± 3.18 hr, and the area under the curve was 24,142 ± 1,096 ng hr ml-1 .","Pharmacokinetics, metabolism and excretion of celecoxib, a selective cyclooxygenase-2 inhibitor, in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30888074/),h,13.60,179748,DB00482,Celecoxib
,30888074,area under the curve,"The elimination half-life was 13.60 ± 3.18 hr, and the area under the curve was 24,142 ± 1,096 ng hr ml-1 .","Pharmacokinetics, metabolism and excretion of celecoxib, a selective cyclooxygenase-2 inhibitor, in horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30888074/),[h·ng] / [ml],"24,142",179749,DB00482,Celecoxib
,31336734,PDI,"The particle size, PDI and zeta potential of optimized CLX-NC were found to be 152.4 ± 1.4 nm, 0.191 ± 0.012 and -34.4 ± 0.6 mV, respectively.","Enhanced Oral Bioavailability of Celecoxib Nanocrystalline Solid Dispersion based on Wet Media Milling Technique: Formulation, Optimization and In Vitro/In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336734/),mv,0.191,185044,DB00482,Celecoxib
,31336734,zeta potential,"The particle size, PDI and zeta potential of optimized CLX-NC were found to be 152.4 ± 1.4 nm, 0.191 ± 0.012 and -34.4 ± 0.6 mV, respectively.","Enhanced Oral Bioavailability of Celecoxib Nanocrystalline Solid Dispersion based on Wet Media Milling Technique: Formulation, Optimization and In Vitro/In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336734/),mv,-,185045,DB00482,Celecoxib
,31336734,zeta potential,"The particle size, PDI and zeta potential of optimized CLX-NC were found to be 152.4 ± 1.4 nm, 0.191 ± 0.012 and -34.4 ± 0.6 mV, respectively.","Enhanced Oral Bioavailability of Celecoxib Nanocrystalline Solid Dispersion based on Wet Media Milling Technique: Formulation, Optimization and In Vitro/In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336734/),mv,34.4,185046,DB00482,Celecoxib
,15386513,flow rate,"The mobile phase consisting of 0.01 M potassium dihydrogen ortho-phosphate (pH 3.2) and acetonitrile (40:60, v/v) was used at a flow rate of 1.0 mL/min.",HPLC method for determination of DRF-4367 in rat plasma: validation and its application to pharmacokinetics in Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386513/),[ml] / [min],1.0,185539,DB00482,Celecoxib
,15386513,Nominal retention times,"Nominal retention times of DRF-4367 and IS were 6.6 and 11.2 min, respectively.",HPLC method for determination of DRF-4367 in rat plasma: validation and its application to pharmacokinetics in Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386513/),min,6.6,185540,DB00482,Celecoxib
,15386513,Nominal retention times,"Nominal retention times of DRF-4367 and IS were 6.6 and 11.2 min, respectively.",HPLC method for determination of DRF-4367 in rat plasma: validation and its application to pharmacokinetics in Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386513/),min,11.2,185541,DB00482,Celecoxib
>,15386513,Absolute recovery,Absolute recovery was >86% from rat plasma for both analyte and IS.,HPLC method for determination of DRF-4367 in rat plasma: validation and its application to pharmacokinetics in Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386513/),%,86,185542,DB00482,Celecoxib
,28748412,maximum observed plasma concentrations (C max),"The maximum observed plasma concentrations (C max) of celecoxib after the administration of DFN-15 120, 180, and 240 mg (1062-1933 ng/ml) were higher than for the 400-mg oral capsules (611 ng/ml).","Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28748412/),[ng] / [ml],1062-1933,187493,DB00482,Celecoxib
,28748412,maximum observed plasma concentrations (C max),"The maximum observed plasma concentrations (C max) of celecoxib after the administration of DFN-15 120, 180, and 240 mg (1062-1933 ng/ml) were higher than for the 400-mg oral capsules (611 ng/ml).","Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28748412/),[ng] / [ml],611,187494,DB00482,Celecoxib
,28748412,time to peak concentration (T max),The median time to peak concentration (T max) was within 1 h for DFN-15 and 2.5 h for the oral capsules.,"Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28748412/),h,1,187495,DB00482,Celecoxib
,28748412,time to peak concentration (T max),The median time to peak concentration (T max) was within 1 h for DFN-15 and 2.5 h for the oral capsules.,"Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28748412/),h,2.5,187496,DB00482,Celecoxib
,28748412,relative bioavailability,"Partial area under the plasma concentration-time curves (AUCs) from 15 min to 2 h for DFN-15 120 mg were at least threefold higher than for the oral capsules, and the relative bioavailability of DFN-15 was approximately 140% that of the oral capsules.","Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28748412/),%,140,187497,DB00482,Celecoxib
,28759842,flow rate,"The Phenomenex column (Kinetex 50×2.1mm i.d. particle size=2.6μm, C18, 100Å) at 25°C was used in chromatographic separation with mobile phase consisting of acetonitrile and water (containing 0.1% formic acid) at flow rate of 0.4mL/min.","Determination of vitacoxib, a novel COX-2 inhibitor, in equine plasma using UPLC-MS/MS detection: Development and validation of new methodology. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28759842/),[ml] / [min],0.4,193617,DB00482,Celecoxib
,28759842,m,"Vitacoxib and internal standard (IS, celecoxib) were detected under the multiple-reaction monitoring mode by mass spectrometer with ESI+ (m/z 347.9/269.03 for vitacoxib and m/z 382.0/362.0 for IS, respectively).","Determination of vitacoxib, a novel COX-2 inhibitor, in equine plasma using UPLC-MS/MS detection: Development and validation of new methodology. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28759842/),,347.9,193618,DB00482,Celecoxib
,28759842,m,"Vitacoxib and internal standard (IS, celecoxib) were detected under the multiple-reaction monitoring mode by mass spectrometer with ESI+ (m/z 347.9/269.03 for vitacoxib and m/z 382.0/362.0 for IS, respectively).","Determination of vitacoxib, a novel COX-2 inhibitor, in equine plasma using UPLC-MS/MS detection: Development and validation of new methodology. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28759842/),,269.03,193619,DB00482,Celecoxib
,28759842,m/,"Vitacoxib and internal standard (IS, celecoxib) were detected under the multiple-reaction monitoring mode by mass spectrometer with ESI+ (m/z 347.9/269.03 for vitacoxib and m/z 382.0/362.0 for IS, respectively).","Determination of vitacoxib, a novel COX-2 inhibitor, in equine plasma using UPLC-MS/MS detection: Development and validation of new methodology. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28759842/),,382.0,193620,DB00482,Celecoxib
,28759842,m/,"Vitacoxib and internal standard (IS, celecoxib) were detected under the multiple-reaction monitoring mode by mass spectrometer with ESI+ (m/z 347.9/269.03 for vitacoxib and m/z 382.0/362.0 for IS, respectively).","Determination of vitacoxib, a novel COX-2 inhibitor, in equine plasma using UPLC-MS/MS detection: Development and validation of new methodology. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28759842/),,362.0,193621,DB00482,Celecoxib
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,231.2,193838,DB00482,Celecoxib
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,346.9,193839,DB00482,Celecoxib
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,285.1,193840,DB00482,Celecoxib
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,382.2,193841,DB00482,Celecoxib
,32622980,bioavailability,"Results obtained indicated that increasing the celecoxib load in the lipid-based formulations by thermally-induced supersaturation resulted in increased bioavailability for medium and long chain mono-/di-glycerides systems relative to their non-supersaturated (i.e. 85%) reference formulations, albeit only significant for the medium chain systems.",Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across PermeapadⓇ membrane and in vivo absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32622980/),%,85,196962,DB00482,Celecoxib
,26280282,flow rate,"Separation was achieved using a Shimadzu liquid chromatography system with a C18 column and mobile phase acetonitrile/water (60:40 and 70:30 for flavones A and B, respectively) containing 0.2% acetic acid and 0.05% triethylamine at a flow rate of 0.4mL/min and detection at 245nm.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),[ml] / [min],0.4,200441,DB00482,Celecoxib
,26280282,Recovery,"Recovery of concentrations 250, 1000, 2500, 5000, and 100,000ng/mL ranged from 87 to 116% and 84 to 103% (n=3) for flavone A and B, respectively.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),%,87 to 116,200442,DB00482,Celecoxib
,26280282,Recovery,"Recovery of concentrations 250, 1000, 2500, 5000, and 100,000ng/mL ranged from 87 to 116% and 84 to 103% (n=3) for flavone A and B, respectively.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),%,84 to 103,200443,DB00482,Celecoxib
≥,26280282,peak ratio,Stability of both flavones after a freezing/thawing cycle yielded a mean peak ratio ≥0.92 when compared to freshly extracted samples.,Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),,0.92,200444,DB00482,Celecoxib
,26280282,half-lives,"Intravenous administration of a 20mg/kg dose in rats yielded half-lives of 83.68±56.61 and 107.45±53.31min with clearance values of 12.99±13.78 and 80.79±35.06mL/min/kg for flavones A and B, respectively.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),min,83.68,200445,DB00482,Celecoxib
,26280282,half-lives,"Intravenous administration of a 20mg/kg dose in rats yielded half-lives of 83.68±56.61 and 107.45±53.31min with clearance values of 12.99±13.78 and 80.79±35.06mL/min/kg for flavones A and B, respectively.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),min,107.45,200446,DB00482,Celecoxib
,26280282,clearance,"Intravenous administration of a 20mg/kg dose in rats yielded half-lives of 83.68±56.61 and 107.45±53.31min with clearance values of 12.99±13.78 and 80.79±35.06mL/min/kg for flavones A and B, respectively.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),[ml] / [kg·min],12.99,200447,DB00482,Celecoxib
,26280282,clearance,"Intravenous administration of a 20mg/kg dose in rats yielded half-lives of 83.68±56.61 and 107.45±53.31min with clearance values of 12.99±13.78 and 80.79±35.06mL/min/kg for flavones A and B, respectively.",Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280282/),[ml] / [kg·min],80.79,200448,DB00482,Celecoxib
,32860356,Peak concentration,Peak concentration of fluorocoxib D (114.8 ± 50.5 ng / ml) was detected in plasma collected at 0.5 h after its administration.,"Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32860356/),[ng] / [ml],114.8,204937,DB00482,Celecoxib
,32860356,tumor-to-normal tissue ratio,Specific tumor-to-normal tissue ratio of detected fluorocoxib D signal was in an average of 3.7 ± 0.9 using Image J analysis.,"Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32860356/),,3.7,204938,DB00482,Celecoxib
,33854925,plasma concentration,The mean plasma concentration of VPA in group A was: 26.9 ± 13.5 mg/L.,Evaluation of sodium valproate low dose efficacy in radicular pain management and it's relation with pharmacokinetics parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33854925/),[mg] / [l],26.9,216588,DB00482,Celecoxib
,34052736,IC50,"All the tested compounds exhibited variable in vitro XO inhibitory activities (IC50 values 0.009-0.077 µM), among which the analog 17 has emerged as the most potent derivative (IC50 0.009 µM), representing nearly 3-times the potency of febuxostat (IC50 0.026 µM).","Febuxostat-based amides and some derived heterocycles targeting xanthine oxidase and COX inhibition. Synthesis, in vitro and in vivo biological evaluation, molecular modeling and in silico ADMET studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34052736/),μM,0.009-0.077,219544,DB00482,Celecoxib
,34052736,IC50,"All the tested compounds exhibited variable in vitro XO inhibitory activities (IC50 values 0.009-0.077 µM), among which the analog 17 has emerged as the most potent derivative (IC50 0.009 µM), representing nearly 3-times the potency of febuxostat (IC50 0.026 µM).","Febuxostat-based amides and some derived heterocycles targeting xanthine oxidase and COX inhibition. Synthesis, in vitro and in vivo biological evaluation, molecular modeling and in silico ADMET studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34052736/),μM,0.009,219545,DB00482,Celecoxib
,34052736,IC50,"All the tested compounds exhibited variable in vitro XO inhibitory activities (IC50 values 0.009-0.077 µM), among which the analog 17 has emerged as the most potent derivative (IC50 0.009 µM), representing nearly 3-times the potency of febuxostat (IC50 0.026 µM).","Febuxostat-based amides and some derived heterocycles targeting xanthine oxidase and COX inhibition. Synthesis, in vitro and in vivo biological evaluation, molecular modeling and in silico ADMET studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34052736/),μM,0.026,219546,DB00482,Celecoxib
,34052736,IC50,"The same analogs were further investigated for their in vitro COX-1 and COX-2 inhibitory activity, where fifteen analogs demonstrated recognizable COX-2 inhibitory potential (IC50 values range 0.04 - 0.1 µM), when correlated with celecoxib (IC50 0.05 µM), together with appreciable selectivity indices.","Febuxostat-based amides and some derived heterocycles targeting xanthine oxidase and COX inhibition. Synthesis, in vitro and in vivo biological evaluation, molecular modeling and in silico ADMET studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34052736/),μM,0.04 - 0.1,219547,DB00482,Celecoxib
,34052736,IC50,"The same analogs were further investigated for their in vitro COX-1 and COX-2 inhibitory activity, where fifteen analogs demonstrated recognizable COX-2 inhibitory potential (IC50 values range 0.04 - 0.1 µM), when correlated with celecoxib (IC50 0.05 µM), together with appreciable selectivity indices.","Febuxostat-based amides and some derived heterocycles targeting xanthine oxidase and COX inhibition. Synthesis, in vitro and in vivo biological evaluation, molecular modeling and in silico ADMET studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34052736/),μM,0.05,219548,DB00482,Celecoxib
,10606360,renal clearance,"The mean renal clearance of MTX alone, 7.98+/-2.18 l/h, was virtually unchanged by coadministration of celecoxib (7.94+/-1.61 l/h) or placebo (7.97+/-1.19 l/h).","Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606360/),[l] / [h],7.98,220587,DB00482,Celecoxib
,10606360,renal clearance,"The mean renal clearance of MTX alone, 7.98+/-2.18 l/h, was virtually unchanged by coadministration of celecoxib (7.94+/-1.61 l/h) or placebo (7.97+/-1.19 l/h).","Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606360/),[l] / [h],7.94,220588,DB00482,Celecoxib
,10606360,renal clearance,"The mean renal clearance of MTX alone, 7.98+/-2.18 l/h, was virtually unchanged by coadministration of celecoxib (7.94+/-1.61 l/h) or placebo (7.97+/-1.19 l/h).","Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606360/),[l] / [h],7.97,220589,DB00482,Celecoxib
,12355578,oral bioavailability,The oral bioavailability of CBX from CBX-BU was dose independent and was in the range 78-96%.,Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355578/),%,78-96,221414,DB00482,Celecoxib
,10497139,plasma elimination half-life,The mean (+/-S.D.) plasma elimination half-life and clearance of celecoxib were 1.72 +/- 0.79 h and 18.2 +/- 6.4 ml/min/kg for EM dogs and 5.18 +/- 1.29 h and 7.15 +/- 1.41 ml/min/kg for PM dogs.,"Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497139/),h,1.72,221539,DB00482,Celecoxib
,10497139,clearance,The mean (+/-S.D.) plasma elimination half-life and clearance of celecoxib were 1.72 +/- 0.79 h and 18.2 +/- 6.4 ml/min/kg for EM dogs and 5.18 +/- 1.29 h and 7.15 +/- 1.41 ml/min/kg for PM dogs.,"Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497139/),[ml] / [kg·min],18.2,221540,DB00482,Celecoxib
,10497139,clearance,The mean (+/-S.D.) plasma elimination half-life and clearance of celecoxib were 1.72 +/- 0.79 h and 18.2 +/- 6.4 ml/min/kg for EM dogs and 5.18 +/- 1.29 h and 7.15 +/- 1.41 ml/min/kg for PM dogs.,"Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497139/),[ml] / [kg·min],7.15,221541,DB00482,Celecoxib
,28370254,ED50,"According to the in vivo results and a comprehensive structure-activity relationship study, five analogs (5, 10, 17, 19, and 27) displayed remarkable anti-inflammatory profiles showing distinctive % protection and ED50 values, especially 10 and 27 (ED50 35.7 and 38.7 μmol/kg, respectively) which were nearly equiactive to celecoxib (ED50 32.1 μmol/kg).","Synthesis, Anti-Inflammatory Activity, and COX-1/2 Inhibition Profile of Some Novel Non-Acidic Polysubstituted Pyrazoles and Pyrano[2,3-c]pyrazoles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370254/),[μM] / [kg],35.7,228009,DB00482,Celecoxib
,28370254,ED50,"According to the in vivo results and a comprehensive structure-activity relationship study, five analogs (5, 10, 17, 19, and 27) displayed remarkable anti-inflammatory profiles showing distinctive % protection and ED50 values, especially 10 and 27 (ED50 35.7 and 38.7 μmol/kg, respectively) which were nearly equiactive to celecoxib (ED50 32.1 μmol/kg).","Synthesis, Anti-Inflammatory Activity, and COX-1/2 Inhibition Profile of Some Novel Non-Acidic Polysubstituted Pyrazoles and Pyrano[2,3-c]pyrazoles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370254/),[μM] / [kg],38.7,228010,DB00482,Celecoxib
,28370254,ED50,"According to the in vivo results and a comprehensive structure-activity relationship study, five analogs (5, 10, 17, 19, and 27) displayed remarkable anti-inflammatory profiles showing distinctive % protection and ED50 values, especially 10 and 27 (ED50 35.7 and 38.7 μmol/kg, respectively) which were nearly equiactive to celecoxib (ED50 32.1 μmol/kg).","Synthesis, Anti-Inflammatory Activity, and COX-1/2 Inhibition Profile of Some Novel Non-Acidic Polysubstituted Pyrazoles and Pyrano[2,3-c]pyrazoles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370254/),[μM] / [kg],32.1,228011,DB00482,Celecoxib
,22382585,progression free survival (PFS),"Median progression free survival (PFS) and overall survival (OS) were 2.7 ms (95% CI, 1.6-3.9 ms) and 7.1 ms (95% CI, 4.3-9.9 ms), respectively.","Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382585/),ms,2.7,232046,DB00482,Celecoxib
,22382585,overall survival (OS),"Median progression free survival (PFS) and overall survival (OS) were 2.7 ms (95% CI, 1.6-3.9 ms) and 7.1 ms (95% CI, 4.3-9.9 ms), respectively.","Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382585/),ms,7.1,232047,DB00482,Celecoxib
greater,22382585,AUC,"Pharmacokinetics of 27 patients (13/14, SD/progressive disease, PD) after the first treatment of UFT revealed that 5-FU AUC and C(max) values greater than 1.313 h × μg/ml and 0.501 μg/ml, respectively, were statistically correlated with stabilization of disease and prolonged PFS/OS.","Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382585/),[h·μg] / [ml],1.313,232048,DB00482,Celecoxib
,22382585,C(max),"Pharmacokinetics of 27 patients (13/14, SD/progressive disease, PD) after the first treatment of UFT revealed that 5-FU AUC and C(max) values greater than 1.313 h × μg/ml and 0.501 μg/ml, respectively, were statistically correlated with stabilization of disease and prolonged PFS/OS.","Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382585/),[μg] / [ml],0.501,232049,DB00482,Celecoxib
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0.24,241866,DB00482,Celecoxib
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0. 29,241867,DB00482,Celecoxib
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0.08,241868,DB00482,Celecoxib
,24586517,sodium excretion,Day 2 urinary electrolyte samples revealed significant reductions in sodium excretion in misoprostol (0.12 ± 0.05 µmol/min/100 g) and misoprostol+celecoxib groups (0.07 ± 0.02 µmol/min/100 g).,Exacerbation of celecoxib-induced renal injury by concomitant administration of misoprostol in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24586517/),[μM] / [100·g·min],0.12,250459,DB00482,Celecoxib
,24586517,sodium excretion,Day 2 urinary electrolyte samples revealed significant reductions in sodium excretion in misoprostol (0.12 ± 0.05 µmol/min/100 g) and misoprostol+celecoxib groups (0.07 ± 0.02 µmol/min/100 g).,Exacerbation of celecoxib-induced renal injury by concomitant administration of misoprostol in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24586517/),[μM] / [100·g·min],0.07,250460,DB00482,Celecoxib
,31629372,extraction recovery,The calibration curve of eight components in plasma showed good linearity (r > .996) and the extraction recovery was 81.19% ± 2.15% - 100.39 ± 3.36 (relative standard deviation: 1.21%-10.70%).,Pharmacokinetic study of eight bioactive components following oral administration of Zhiqiao Gancao decoction and observation of its clinical efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31629372/),%,81.19,251523,DB00482,Celecoxib
,31629372,extraction recovery,The calibration curve of eight components in plasma showed good linearity (r > .996) and the extraction recovery was 81.19% ± 2.15% - 100.39 ± 3.36 (relative standard deviation: 1.21%-10.70%).,Pharmacokinetic study of eight bioactive components following oral administration of Zhiqiao Gancao decoction and observation of its clinical efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31629372/),36,100.39,251524,DB00482,Celecoxib
,10749518,apparent volume of distribution,"Celexocib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 455+/-166L in humans.",Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),l,455,252478,DB00482,Celecoxib
,10749518,elimination half-life,Celecoxib is metabolised primarily by the cytochrome P450 (CYP) 2C9 isoenzyme and has an elimination half-life of about 11 hours in healthy individuals.,Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),h,11,252479,DB00482,Celecoxib
≤,21704141,LOD,"Two simple, fast and validated RP-HPLC methods were developed for simultaneous quantitative determination of the amides and celecoxib in aqueous and biological samples and LOD and LOQ were ≤13.6 and ≤40ng/mL, respectively.",Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704141/),[ng] / [ml],13.6,256062,DB00482,Celecoxib
≤,21704141,LOQ,"Two simple, fast and validated RP-HPLC methods were developed for simultaneous quantitative determination of the amides and celecoxib in aqueous and biological samples and LOD and LOQ were ≤13.6 and ≤40ng/mL, respectively.",Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704141/),[ng] / [ml],40,256063,DB00482,Celecoxib
,21704141,half-lives,"Significant hydrolysis was observed for MP-CXB at pH 1.2 only with half-lives 28.28, 11.64 and 3.53h at 60, 70 and 80°C, respectively, with extrapolated half-lives of 2060 and 443h at 25 and 37°C, respectively.",Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704141/),h,28.28,256064,DB00482,Celecoxib
,21704141,half-lives,"Significant hydrolysis was observed for MP-CXB at pH 1.2 only with half-lives 28.28, 11.64 and 3.53h at 60, 70 and 80°C, respectively, with extrapolated half-lives of 2060 and 443h at 25 and 37°C, respectively.",Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704141/),h,11.64,256065,DB00482,Celecoxib
,21704141,half-lives,"Significant hydrolysis was observed for MP-CXB at pH 1.2 only with half-lives 28.28, 11.64 and 3.53h at 60, 70 and 80°C, respectively, with extrapolated half-lives of 2060 and 443h at 25 and 37°C, respectively.",Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704141/),h,3.53,256066,DB00482,Celecoxib
,21704141,half-lives,"Significant hydrolysis was observed for MP-CXB at pH 1.2 only with half-lives 28.28, 11.64 and 3.53h at 60, 70 and 80°C, respectively, with extrapolated half-lives of 2060 and 443h at 25 and 37°C, respectively.",Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704141/),h,2060,256067,DB00482,Celecoxib
,21704141,half-lives,"Significant hydrolysis was observed for MP-CXB at pH 1.2 only with half-lives 28.28, 11.64 and 3.53h at 60, 70 and 80°C, respectively, with extrapolated half-lives of 2060 and 443h at 25 and 37°C, respectively.",Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704141/),h,443,256068,DB00482,Celecoxib
,21704141,half-life,The hydrolysis of all amides was studied in rat live homogenate and only Cy-CXB was hydrolyzed with half-life of 3.79h.,Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704141/),h,3.79,256069,DB00482,Celecoxib
,34323638,Selectivity Index,"Among these flavones, only F2 exhibited selectivity toward COX-2 (Selectivity Index, SI: 3.90, COX-2 inhibition: 98.96 ± 1.47%) in comparison with celecoxib (SI: 7.54, COX-2 inhibition: 98.20 ± 2.55%).","Discovery of polymethoxyflavones as potential cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX) and phosphodiesterase 4B (PDE4B) inhibitors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34323638/),,3.90,266637,DB00482,Celecoxib
>,34323638,IC50,"Interestingly, F1-F5 displayed favorable pharmacokinetic profiles and acceptable range of toxicity (IC50>70 µM) in cell lines with the exception for F1 (IC50: 16.02 ± 1.165 µM).","Discovery of polymethoxyflavones as potential cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX) and phosphodiesterase 4B (PDE4B) inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34323638/),μM,70,266638,DB00482,Celecoxib
,34323638,IC50,"Interestingly, F1-F5 displayed favorable pharmacokinetic profiles and acceptable range of toxicity (IC50>70 µM) in cell lines with the exception for F1 (IC50: 16.02 ± 1.165 µM).","Discovery of polymethoxyflavones as potential cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX) and phosphodiesterase 4B (PDE4B) inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34323638/),μM,16.02,266639,DB00482,Celecoxib
,13680854,flow-rate of the mobile phase,The flow-rate of the mobile phase was set at 1 mL/min.,Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13680854/),[ml] / [min],1,269115,DB00482,Celecoxib
>,13680854,extraction efficiency,The extraction efficiency was >80% for both rosiglitazone and IS from human plasma.,Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13680854/),%,80,269116,DB00482,Celecoxib
